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The main goal of this PhD thesis was the search for male fetal microchimeric cells in blood of patients 
with an autoimmune thyroid disease (Part II). Through the course of this PhD thesis, optimization of 
protocols for forensic hair and blood analysis was also performed (Part III).  
Objects in the range of 0.1 mm can be seen with the naked eye. However, for the visualization of 
smaller items, visualization aids are necessary. In many biological samples, the use of a (light or 
electron) microscope is essential to visualize cellular and subcellular structures. Light microscopy can 
be used to visualize plant or animal cells and bacteria and can resolve details 0.2 µm apart, while 
smaller molecules can be visualized with an electron microscope, resolving details 0.1 nm apart 
(Figure 1). 
 
 
 
Figure 1: Resolving power.  Sizes of cells 
and their components are drawn on a 
logarithmic scale, indicating the range of 
objects that can be seen by the naked 
eye and by light (and electron) 
microscopes [1].  
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Most cells however, are hardly visible through a light microscope without staining techniques. 
Staining techniques in this thesis were performed on non-living cells. Therefore, fixation prior to 
staining is necessary to preserve cellular components, prevent autolysis and displacement of cell 
constituents, and to stabilize cellular materials against deleterious effects of subsequent procedures. 
There are two types of fixations which are commonly used: cross-linking fixatives such as 
formaldehyde and coagulating fixatives such as ethanol [2]. In addition, if intracellular structures 
have to be stained, permeabilization of the cell membrane may be required. Commonly used 
reagents to permeabilize the cell are detergents such as Triton X-100 or NP-40. 
Several specific and non-specific staining techniques have been developed. Non-specific stains 
generally have affinities for certain categories of molecules such as basic proteins, nucleic acids, 
lipids or carbohydrates [3]. Examples of non-specific, cytological stains are hematoxylin and eosin 
(H&E), which are commonly used in histology. Hematoxylin stains the nuclei blue whereas eosin 
stains cytoplasm, connective tissue and other extracellular substances pink or red. However, more 
specific staining methods are required to study specific proteins or other molecules in cells.  
In general, fluorescent stains have a higher discriminatory power than cytological stains [4]. 
Fluorescence is the emission of light that occurs within nanoseconds after the absorption of light by a 
fluorescent molecule and is typically of a longer wavelength than the excitation light. The difference 
between the excitation and emission wavelengths, known as the Stokes shift, is the critical property 
that makes fluorescence so powerful. Emission photons are isolated from excitation photons by 
appropriate filter sets. The value of fluorescence microscopy lies in the fact that, unlike other modes 
of optical microscopy which are based on macroscopic specimen features, fluorescence microscopy is 
capable of imaging with very high contrast. The use of fluorochromes has made it possible to identify 
specific proteins or other molecules in cells and tissues, with a high degree of specificity against non-
fluorescing material. Moreover, the fluorescence microscope can reveal the presence of fluorescing 
material with exquisite sensitivity as molecules of interest are often present in extremely small 
amounts in the specimen. Several fluorescent stains can be combined to reveal simultaneously the 
presence of individual target molecules. The major limitation of using fluorochromes is that they lose 
their ability to fluoresce when they are continuously illuminated, a process called photobleaching. 
However, minimizing illumination or using antifade reagents such as Vectashield can overcome this 
problem [5]. 
Many fluorochromes have been developed for their use in the field of fluorescence microscopy. DAPI 
or 4,6’-diamidino-2-phenylindole is one of the most commonly used fluorochromes. DAPI is excited 
by ultraviolet light and shows strong blue fluorescence when bound to nucleic acids, preferentially to 
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adenosine and thymidine base pair regions [6]. DAPI can be used to detect cell nuclei in tissue 
sections or cell specimens (Part II) or can be used to visualize nuclei in hair roots (Part III).  
Fluorescence microscopy has many clinical and forensic applications [1,4]. In immunofluorescence, a 
sample is treated with a primary antibody specific for the antigen of interest. A fluorochrome can be 
directly conjugated to the primary antibody. Alternatively, a secondary antibody conjugated to a 
fluorochrome which binds specifically to the first antibody, can be used. An example of a secondary 
antibody staining is shown in Figure 2.  
 
Figure 2 : In thyroid glands, T cells are stained red (mouse anti-CD3 antibody (primary) and goat anti-mouse 
antibody conjugated with AF594 (secondary)), while B cells are stained green (rabbit anti-CD79α antibody 
(primary) and goat anti-rabbit antibody conjugated with AF488 (secondary)).  
Cell nuclei are stained blue with DAPI. 
 
Fluorescence microscopy can also be used in combination with fluorescent probes to detect and 
localize the presence or absence of specific DNA sequences on chromosomes. This can be achieved 
using the fluorescent in situ hybridization (FISH) staining technique. Fluorescent probes bind only to 
those parts of the chromosome with which they show a high degree of sequence complementarity. 
Three main types of chromosome-specific probes are commonly used in FISH: repetitive sequence 
DNA probes, locus-specific DNA probes and whole chromosome painting probes. Centromeric 
repetitive sequence DNA probes are often applied for interphase cytogenetics as a strong fluorescent 
signal can be generated due to the many tandem repeated copies of the target sequence [7,8]. FISH 
can be used in genetic counseling (e.g. Down Syndrome), medicine (e.g. for diagnosis), or species 
identification (e.g. pathogen identification) [9]. FISH can also be used to detect specific RNA targets in 
cells, circulating tumor cells and tissue samples.  
The principle of FISH is shown in Figure 3. Cells must first be fixed and made permeable to allow 
target accessibility. Subsequently, the target DNA is denatured to produce single-stranded DNA. The 
probe is then applied to the slide to hybridize for approximately 12 hours. Several wash steps are 
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performed to remove all unhybridized probes. Subsequently, DNA sequences of interest can be 
visualized using a fluorescence microscope [10].  
 
Figure 3: Principle of Fluorescent in situ hybridization 
(http://nl.wikipedia.org/wiki/Fluorescent_in_situ_hybridization) 
FISH can, for example, be used to discriminate between male and female cells by using X and Y 
chromosome specific probes (Figure 4). This can be important in the detection of male fetal 
microchimeric cells in female patients with an autoimmune disease (Part II). 
 
Figure 4: One male cell indicated with an arrow (one green Y-chromosomal spot and one red X-chromosomal 
spot), against a background of female cells (2 red X-chromosomal spots). 
Cell nuclei are stained blue with DAPI. 
Fluorescence microscopy can also be used for several forensic applications, e.g. for the detection of 
spermatozoa in a background of female epithelial cells in post-coital samples. FISH has also its 
applications in forensics, e.g. for the detection of male cells in a mixture with female cells in cases of 
sexual assault [11-13].  
More than meets the eye 
 
 
 
21 
As described earlier, DAPI can be used to stain cell nuclei in tissue sections and cell specimens. 
Another application of DAPI can be found in the staining of nuclear DNA in hair roots. This can be 
important in forensic hair analysis to predict the DNA analysis success rate (Part III, Chapter 2)  
(Figure 5). 
 
Figure 5: DAPI-staining of a hair root showing many visible nuclei. 
 
Through the course of this PhD thesis, optimization of a visualization protocol for blood analysis was 
also performed. Bloodstains on dark fabrics are hard to observe with the naked eye. Therefore, a 
simple visualization assay using wet filter paper and pressure can be used to reveal bloodstains on 
dark fabrics, which is described in Part III, Chapter 3. 
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The main focus of this PhD thesis was the detection of male fetal microchimeric cells in autoimmune 
thyroid diseases in order to investigate their potential role in the pathogenesis of these diseases 
(Part II). Autoimmune diseases show a female predominance and occur more often in the years 
following parturition [1]. Several hypotheses have been suggested to explain this gender difference, 
including differences in sex hormones, stronger immune reaction in women and X-chromosome 
abnormalities [2]. Another hypothesis suggests that fetal microchimeric cells, able to persist 
postpartum in the maternal circulation and tissues, are responsible for this gender difference [3]. An 
introduction to fetal microchimerism, detection methods and long-term consequences of post-
partum persistence of these cells are described in depth in Chapter 1. In Chapter 2, the aim and 
outline of this part of the thesis are presented. Fetal microchimerism has been associated with 
several autoimmune and non-autoimmune diseases. In autoimmune thyroid diseases however, these 
cells have not been characterized. Characterizing these fetal cells would be very interesting to 
elucidate the potential role of fetal microchimeric cells in autoimmune thyroid diseases. In a 
following chapter, an introduction to autoimmune thyroid diseases is given (Chapter 3). In search for 
the potential role of fetal microchimeric cells in autoimmune thyroid diseases, blood of these 
patients was analyzed for the presence of male fetal microchimeric cells using FISH (Chapter 4). 
Several hypotheses concerning the potential role of fetal microchimerism in autoimmune and non-
autoimmune diseases have been proposed, in which fetal cells have harmful, beneficial or innocent 
effects. In autoimmune thyroid diseases, only the presence of fetal microchimeric cells in blood and 
in the thyroid gland has been proven, but not an actual active role. In Chapter 5, a discussion 
concerning the potential harmful, beneficial or innocent role of these fetal microchimeric cells in 
autoimmune thyroid diseases is described. At the end of this thesis, data obtained in blood are 
reflected against existing data in thyroid glands (Addendum). 
In Part III, a screening method for the selection of hairs suitable for forensic DNA analysis and a 
visualization assay for the detection of bloodstains on dark fabrics are presented (Chapter 1). Human 
hairs are frequently recovered as forensic evidence as humans shed about 150 hairs daily. The 
success rate of Short Tandem Repeat (STR) profiling of these hair roots is however quite low and 
negative results of hair analysis are frequently reported. To increase the success rate of DNA analysis 
of hairs in forensics, nuclei in hair roots can be visualized using the fluorescence microscope after 
staining the hair root with DAPI (Chapter 2). Bloodstains on dark fabrics are not always visible 
without visualization techniques. In Chapter 3, a visualization assay based on the application of 
pressure and wet filter paper is presented.  
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1. Female predominance of autoimmune diseases 
The immune system is a complex network of cellular and protein components designed to protect 
the individual from invasion by pathogens. Therefore, the immune system has to be able to 
differentiate between ‘self’ and ‘non-self’ antigens. Recognition of ‘non-self’ leads to the 
neutralization or destruction of foreign pathogens. Autoimmunity occurs when the immune system 
starts recognizing ‘self’ as ‘non-self’  and attacks the tissues of its own host, causing tissue damage 
and thereby leading to disease. In a normal state, self-reactive lymphocytes are deleted in the 
thymus gland (central tolerance). The few autoreactive T cells that escape central tolerance are 
eliminated by peripheral tolerance mechanisms [1]. If these regulatory mechanisms fail,  
autoimmune diseases can occur [2]. 
There are more than 80 different known autoimmune diseases which can range from organ-specific 
diseases (e.g. thyroid gland in Graves’ disease) to generalized multi-system disease (e.g. systemic 
sclerosis). Autoimmune diseases affect up to 5% of the population [3] and are characterized by 
inflammation and the production of a wide range of autoantibodies directed against multiple auto-
antigens. Although their etiology is still poorly understood, genetic, immunological, hormonal, and 
environmental factors are major predisposing and triggering factors [4].  
As a group, autoimmune diseases are more common in adults than in children, and more common in 
females than in males [3,5,6]. The female: male ratio for some autoimmune diseases is shown in 
Table 1. 
Table 1: Gender ratio (female: male) of a few autoimmune diseases [3,7-9]. 
Autoimmune Disease F: M ratio 
Graves’ disease 3,5 – 7,2 : 1 
Hashimoto’s thyroiditis 5,2 – 50  : 1 
Multiple sclerosis 1,8 – 4,3 : 1 
Primary biliary cirrhosis 7,8 – 16 : 1 
Rheumatoid arthritis 2,7 –  4 : 1 
Systemic sclerosis 3,0 – 11,8 : 1 
Sjörgen’s syndrome 4,0 – 20 : 1 
Systemic lupus erythematosus                                            7,4 – 10 : 1
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The precise cause of this gender bias remains unknown and relatively few hypotheses have been 
proposed to explain why women are more prone to autoimmune diseases, including differences in 
sex hormones, stronger immune reaction in women and X-chromosome abnormalities. Estrogens, 
androgens and prolactin have been the first proposed candidates to have important roles in the sex 
bias observed in autoimmunity due to their capacity of modulating the immune response through 
androgen and estrogen receptors. Progenitor and mature cells express both receptors. These sex 
hormones could have a direct influence on the homing of lymphocytes to target organs and antigen 
presentation [4,9]. Estrogens act as enhancers of humoral activity by enhancing the production of 
IFNγ, IL-1 and IL-10, while androgens and progesterone act as immune suppressors by suppressing 
the production of IL-4 and IL-5. Prolactin stimulates both cell and humoral-based immunity [10]. 
However, no significant differences in hormone levels between women with an autoimmune disease 
and healthy control persons were observed, indicating that other gender associated differences are 
attributing to the high female predominance in autoimmune disorders [9,11]. Furthermore, 
exogenously administered sex hormones do not have similar effects on different autoimmune 
diseases or on susceptibility to the disease [12]. Although sex hormone levels increase during 
pregnancy, pregnancy has dissimilar effects on several autoimmune diseases (e.g. pregnancy 
commonly induces remission of rheumatoid arthritis but not of systemic lupus erythematosus) 
[12,13]. 
Women show a stronger, more vigorous humoral (antibody-mediated) immune reaction compared 
to men and have increased cell-mediated responses following immunization, while men produce a 
more intense inflammatory response to infectious organisms [11]. However, the significance of these 
differences remains poorly defined since there does not appear to be significant differences in 
susceptibility to infection or inflammation degrees between both sexes [9]. 
X chromosome abnormalities such as skewed X chromosome inactivation and mutations of X 
chromosome genes, have also been suggested as possible explanation for the female predominance 
of autoimmune diseases. X chromosome inactivation is an epigenetic regulation in early 
development that results in transcription inactivation of one of the two X chromosomes. As a result, 
the X chromosome inherited from either parent is silenced at random, and normal women are thus a 
mosaic of two cell populations. It is therefore conceivable that skewed X chromosome inactivation, 
when one of the two alleles (either from mother or father) is in the active X  chromosome in more 
than 75% of cells, could lead to the escape of X-linked self-antigens from presentation in the thymus 
or in other peripheral sites that are involved in tolerance induction, inadequate thymic deletion, and 
finally, loss of T cell tolerance [10,14]. Examination of X chromosome inactivation patterns, by 
analyzing the methylation status of a highly polymorphic CAG repeat in the androgen receptor gene, 
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in peripheral blood from female patients with autoimmune diseases, such as systemic lupus 
erthematosus, did not reveal skewed X chromosome inactivation patterns [15]. In scleroderma 
however, a severely skewed X chromosome inactivation pattern was found in blood of these patients, 
but not in their skin lesions [14]. Skewed X-chromosome inactivation was also observed in 34% of 
female twins with autoimmune thyroid disease in contrast to 11% of the healthy controls [16,17]. 
Although skewed X chromosome inactivation alone does not explain the pathogenesis of 
autoimmune diseases, it can be an extra factor influencing the occurrence. Specific mutations of X 
chromosome genes cause immunodeficiency syndromes characterized by different degrees of 
severity. FoxP3, encoded by a gene localized in the short arm of the X chromosome, is essential for 
regulatory T cells and its deficiency or mutation leads to an early onset, highly aggressive, and often 
fatal multi-organ autoimmune disease [18]. 
However, none of the above mentioned reasons alone could explain the female predominance of 
autoimmune diseases. As most human autoimmune diseases develop preferentially in women of 
childbearing age and some autoimmune diseases, such as systemic sclerosis, show some clinical 
similarities with chronic graft-versus-host disease (cGvHD) after allogeneic bone marrow 
transplantation, another hypothesis has been suggested to explain the female predominance of 
autoimmune diseases: the presence of fetal microchimeric cells postpartum [12].  
2. Fetal microchimerism 
During pregnancy, fetal cells cross the placenta and enter into the maternal circulation (Figure 1) 
[19,20]. This fetal cell trafficking was first described by Georg Schmorl in 1893 when multi-nucleated 
syncytial giant cells were identified in the lungs of women who had died from preeclampsia. Schmorl 
speculated that these cells were of placental origin [21,22]. Seventy years later, male cells were 
detected in peripheral blood of parous women expecting a boy [23,24].  
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Figure 1: Cell traffic during pregnancy is bidirectional for maternal and fetal cells [25]. 
The term chimerism was first used by Liegeois in 1977 [26]. In Greek mythology, a chimera combines 
parts of different animals: a lion, a goat and a snake (Figure 2). In biology, the word chimerism can be 
used to refer to the existence of cells from genetically distinct individuals in one person.  
 
Figure 2: chimera. (http://www.ksl.stanford.edu/software/chimaera/) 
If this genetically distinct cell population is less than 1% of the total amount of cells, the term 
microchimerism is used. Fetal microchimerism refers to the presence of fetal cells in the mother 
during and after pregnancy, and is a well-known phenomenon in healthy persons as well as persons 
with a disease [27,28]. 
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Fetal microchimerism is a natural consequence of normal pregnancy and results from deficiencies in 
the natural placental trophoblastic physical barrier tissue that separates the maternal circulation 
from the fetal circulation. A certain leakage is present between mother and fetus during pregnancy, 
and this transplacental cell trafficking is a two-way process: fetal microchimeric cells can be detected 
in the mother [29] and maternal microchimeric cells can be detected in the fetus/child [30].  
In pregnancy, a fetal ‘graft’ that carries paternal and maternal antigens is by definition partially 
allogeneic. For a successful pregnancy, the maternal immune system must not overreact to the fetus. 
Several local and systemic mechanisms make sure that the fetus is not rejected by the mother, 
including synthesis of indoleamine 2,3-dioxygenase (IDO) and the expression of HLA-G by the 
syncytiotrophoblast, and a shift in Th1/Th2 balance [31]. These mechanisms indicate that pregnancy 
is not associated with a generalized state of immune suppression, but rather with a state of selective 
tolerance. Immune suppression of maternal immunity during pregnancy may play an important role 
in allowing the establishment of fetal microchimerism [25,32].  
Fetal microchimeric cells can be detected in the maternal circulation from the 4
th
 to 6
th
 week of 
gestation [33-35]. Their quantity rises with gestation to peak at delivery [36]. Fetal cells can be found 
in the peripheral blood of almost 100% of women during the third trimester of pregnancy [37]. 
Quantitative studies on bi-directional transfer of cells revealed lower cell passage from mother to 
fetus compared to cell passage from fetus to mother [19]. The level of circulating fetal cells has been 
reported to be very low (2 to 6 fetal cells per ml of maternal blood during the second trimester) 
[38,39]. Not only do completed pregnancies result in the presence of fetal microchimeric cells in the 
mother, fetal microchimerism has also been described in women having a miscarriage or induced 
abortion. Moreover, terminations of pregnancies were associated with an elevated number of 
detectable fetal microchimeric cells [40-44]. In the second trimester, the number of fetal cells in the 
maternal circulation before and after a termination increases from about 1 to 100 per ml of maternal 
whole blood [40]. The number of fetal microchimeric cells in the maternal circulation is also 
increased by fetal and placental abnormalities, including fetal aneuploidy such as trisomy 21 [45], 
intrauterine growth retardation [46] and maternal preeclampsia [47,48].  
Under normal circumstances, most fetal cells are lost during the postpartum period [32,33]. However, 
30 to 50% of all women have detectable fetal cells in their blood [49] and tissues [29,42,50-55] 
decades after pregnancy, which indicates incomplete elimination of fetal cells [56]. Once fetal cells 
take up residence in maternal tissues [57-59] such as the thyroid gland, they may survive without 
being destroyed. This can be due to maternal immune adaptations during pregnancy [60], which may 
remain for a few months after delivery [56] allowing fetal cells to establish themselves and to survive 
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the postpartum period [25]. Systemic evaluation of normal organs for male cells by FISH identified 
male cells in thyroid, lung, lymph node and skin in women with sons and in kidney, liver and heart in 
women with and without sons [53]. In mice, intact fetal cells were detected in a number of maternal 
organs, including bone marrow, lung, heart and kidney during pregnancy [61]. Fetal cells are typically 
concentrated in the lungs, liver, and spleen, presumably reflecting the large blood supply of these 
organs [62].  
The most plausible explanation described for this fetal cell persistence is the engraftment of these 
cells into maternal bone marrow, providing a renewing source of fetal cells in maternal blood for 
decades after delivery [63]. In accordance to Nelson et al. [64], we believe that human leukocyte 
antigen (HLA) relationship between mother and fetus is a more determining factor whether or not 
fetal microchimeric cells can persist in the maternal circulation and/or tissues postpartum. Increased 
HLA class II compatibility between mother and children was observed in women with detectable fetal 
microchimerism. These results led to the hypothesis that fetal cells may have crossed the placental 
barrier and remained unrecognized due to this HLA compatibility, establishing a low-grade, long-term 
state of microchimerism [65]. 
A recent publication stated that we are all born as microchimera [66]. Other natural sources of 
microchimerism besides pregnancy include cell transfusion from a twin, either a surviving twin or a 
vanished twin (i.e. cell transfer from a twin in utero which was lost early in gestation) and transfer of 
cells from an older sibling through the maternal circulation [42,44,66-71]. Iatrogenic causes of 
chimerism comprise blood transfusions and bone marrow or solid organ transplantations (such as 
kidney and heart transplantation) [72,73]. These alternative sources for microchimeric cells should 
be taken into account when investigating fetal microchimerism. 
3. Detection of fetal microchimerism 
3.1. Detection techniques 
To identify male fetal microchimeric cells in women with a previous male pregnancy, male-specific 
gene markers can be used. Although the Y chromosome is the only universal marker of fetal 
microchimerism, it does not distinguish between the contributions from different male fetuses [74].  
In general, two techniques have been most widely used to identify male fetal microchimerism: PCR 
targeting sequences specific to Y chromosome genes (e.g. DYS14 and SRY) [27,75] and Fluorescence 
in situ Hybridization (FISH) using X and Y chromosome specific probes [76].  
While PCR only indicates the presence of fetal cells and estimates the amount of fetal microchimeric 
cells [77], FISH gives an exact number [76,78]. Both techniques have a different sensitivity [79]. With 
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PCR, a single male cell can be detected within a background of 100.000 female cells [32,44,80] 
compared to 1 male cell within 2.000.000 female cells with FISH [81]. 
For PCR-based approaches, genomic DNA is typically extracted from blood (whole blood, plasma or 
peripheral blood mononuclear cells (PBMCs)) or tissues. A sequence unique to the fetus is selected 
for PCR amplification. In pregnancies where the gender of the fetus is male or when a woman is 
known to have previously given birth to a son, sequences specific to Y chromosome genes (DYS14, 
SRY) are targeted by the primers. When the fetus or child has been previously genotyped for 
paternally derived polymorphisms, allele specific PCR can also be used. HLA offers a broader 
applicable target for microchimerism detection as they are highly polymorphic and thus frequently 
mismatched between two individuals [82-85]. However, its sensitivity is much lower than PCR and 
FISH. Minimum 5 fetal cells have to be present among 100.000 maternal cells in order to be able to 
detect them [83,86]. 
Whereas the PCR-based methods of Y chromosomal detection only demonstrate the presence of 
male cells, other methodologies such as immunocytochemistry, FISH and HLA typing identify the 
location, the phenotype and the immunogenetic properties of microchimeric cells in a variety of 
tissues [87-89]. Moreover, the source of the microchimeric cells can be determined [49,57,90]. FISH 
with probes targeting X and Y chromosomes can be used to identify male cells in blood and tissues of 
women (Figure 3).  
 
Figure 3: One male cell indicated with an arrow (one green Y-chromosomal spot and one red X-chromosomal 
spot), against a background of female cells (2 red X-chromosomal spots). 
DAPI staining was performed to stain the cell nuclei blue. 
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Besides the ability to localize fetal microchimeric cells in tissue sections and the possibility to 
combine it with immunochemistry staining methods, FISH is less subject to contamination than PCR 
amplification [76]. A disadvantage of FISH is that overlapping cells can produce artifacts, implying the 
need for time and labor intensive experiments. Despite this disadvantage, FISH using X and Y 
chromosomal probes was used in our research to detect fetal microchimeric cells in patients with an 
autoimmune thyroid disease. 
Techniques based on sex differences are currently limited by the lack of any information on female 
microchimeric cells, which potentially have the same consequences on maternal health as male 
microchimeric cells [80]. Targeting other genetic polymorphisms in tissue sections has been 
proposed to overcome this limitation. Focus has been put on deletion polymorphisms to develop 
informative FISH probes with the ability to distinguish between donor and recipient cells [91]. 
Alternatively, female fetal cells can be assessed by HLA-based detection but are more difficult to 
study because this system requires multiple detection probes [32].  
FISH has been postulated to be problematic due to the frequency of false positive FISH signals and 
difficulties with the attribution of FISH spots to particular nuclei in tissue sections. Therefore, 
isolation of single candidate microchimeric cells by laser microdissection and pressure catapulting 
(LMPC) and low-volume on-chip multiplex PCR for DNA fingerprint analysis to identify the 
microchimeric cells has been proposed. Multiplex PCR using microsatellite loci allows sex-
independent identification of cells and molecular genetic diagnosis by analysing specific monogenetic 
genomic disease markers [92].  
Not only intact fetal cells have been studied, but also cell-free fetal DNA, primarily derived from 
apoptotic shedding of trophoblast material [19]. However, in contrast to fetal cellular 
microchimerism, cell-free fetal DNA and fetal erythroblasts are rapidly and definitively cleared from 
the maternal system postpartum [93]. Therefore, cell-free fetal DNA is less interesting to study.  
In the study of fetal microchimerism, animal models can be used. In murine experiments, allogeneic 
male mice homozygous for green fluorescent protein (GFP) expression, were mated with wild type 
female mice, upon which green fluorescent fetal cells were detected in blood, bone marrow and 
thyroid gland of pregnant mice [94], and in maternal brain postpartum [95]. Advantages of these 
animal studies are the low gestational period and the opportunity to control breeding between 
transgenic male mice carrying the GFP gene and wild type female mice. Moreover, microchimeric 
cells can be well defined by immunohistochemistry or can be microdissected from the maternal 
tissue for further investigation [96].  
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There are technical issues to consider in the interpretation of results from studies of microchimerism. 
Because fetal microchimerism is a low-frequency event, issues of interlaboratory variability, 
experimental design, sensitivity and specificity of the techniques are important variables which may 
lead to different results and conclusions [97,98]. Variations in experimental design are demonstrated 
in a direct comparison between PCR of whole blood DNA and PCR of DNA from magnetically sorted 
cells for the detection of microchimeric cells. Magnetic cell sorting before PCR increased the 
sensitivity of detecting male cells by 200-fold [99]. Whole peripheral blood DNA may therefore not 
be useful for the reliable detection of microchimeric cells, possibly because of the high background of 
autologous cells [100]. Moreover, data using fresh frozen material cannot be compared to data 
obtained from paraffin-embedded tissue because the latter is subject to DNA fragmentation which 
leads to misinterpretation of the data [27]. Pathologists do not routinely change paraffin baths 
between samples. Another technical issue is the choice of the particular Y chromosome sequence. 
Some Y chromosome sequences cross-react with autosomal sequences. Multi-copy sequences have 
greater sensitivity than single-copy sequences (e.g. SRY), but some Y chromosome sequences vary in 
copy number from individual to individual and could give spurious results in quantitative assays (e.g. 
DYZ1). In FISH, overlapping cells in histological sections can produce artefacts. Therefore, only cells 
with two signals in a well-defined nucleus should be counted [101].  
Furthermore, clinical variables such as pregnancy history and medication intake, should be taken into 
consideration [79,102]. Some reports lack pregnancy history or do not provide it in conjunction with 
the results of microchimerism tests. Alternative sources of microchimerism should be considered and 
duration of disease and therapy should be specified [101]. 
3.2. Fetal microchimeric cell types 
During pregnancy, fetal microchimeric cells entering the maternal circulation are predominantly of 
hematopoietic origin such as nucleated red blood cells, T and B lymphocytes, monocytes and natural 
killer cells or CD34
+
 and CD34
+
CD38
+
 hematopoietic stem cells [29,36,103,104]. Even fetal 
mesenchymal stem cells [52,105,106] and endothelial progenitor cells [107] have been reported. As 
trophoblastic cells serve as lining cells in contact with the maternal circulation, it is not surprising to 
find these cells in the maternal blood as a result of cell shedding [108]. The establishment of fetal 
CD34
+
 or CD34
+
CD38
+
 cells in the maternal lymphoid organs or bone marrow may help to maintain 
tolerance to the fetal graft [29]. Fetal cells in pregnant mice express both progenitor and 
differentiated cell markers [109].  
To persist after delivery, fetal microchimeric cells must have the ability for long-term engraftment in 
the maternal host and must therefore share properties with stem cells, such as unlimited self-
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renewal ability and plasticity for multilineage differentiation [49,110]. These cells were termed 
pregnancy-associated progenitor cells (PAPCs) [57]. Their stemness is supported by the diversity of 
detected fetal phenotypes (Figure 4) and the variety of tissues into which they integrate [49,61,109]. 
The finding that fetal cells in maternal bone marrow harbor the potential to differentiate into 
different lineages, supports the idea that PAPCs might originate from one multipotent fetal stem cell 
type rather than being a mixture of various, less potent progenitors. However, the cellular origin of 
PAPCs remains elusive [74,111,112]. Whether the fetal cells actually differentiate or fuse with the 
damaged host cells, remains an open question. However, using chromosome-specific probes and 
FISH, tetraploid signals consistent with such a fusion were never observed [49,90]. In a murine model, 
fetal cell maturation into neurons has been demonstrated in the maternal brain, and fusion was 
effectively ruled out [113]. 
 
Figure 4: Fetal microchimeric cells traffic into maternal tissues and differentiate into  
cell types of ectodermal, endodermal, and mesodermal lineages [114]. 
 
In the postpartum period, fetal microchimerism has been described in healthy persons and persons 
with a disease. Combining FISH and immunochemistry, the phenotype of fetal microchimeric cells 
could be determined (Table 2).  
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Table 2 : Reported phenotypes of fetal microchimeric cells in human maternal tissues postpartum 
(adapted from [114]). 
Microchimeric 
Cell Type 
Tissue Disease/injury Phenotype Reference 
Epithelial 
Thyroid, cervix, 
intestine, 
gallbladder 
Healthy Cyto-keratin
+
 [57] 
Cervix Cancer Cyto-keratin
+
 [115] 
Thyroid Goiter 
Differentiation into 
thyroid follicle 
[76] 
Hepatic 
Liver Healthy Heppar-1 [57] 
Liver 
Hepatitis C infection or 
primary biliary cirrhosis or 
steatosis 
CAM-5.2 [90] 
Liver Hepatitis C infection  [116] 
Hematopoietic 
Blood Healthy 
CD34
+
, CD34
+
CD38
+ 
lymphoid progenitors 
[29] 
Blood Healthy and SSc 
CD3
+
, CD19
+
, CD14
+
, 
CD56/CD16 
[50] 
Lymph nodes, 
spleen 
Healthy CD45
+
 [57] 
Blood G-CSF mobilized apharesis CD34
+
 [28] 
Blood Healthy CD34
+
 [104,117] 
Mesenchymal 
Bone marrow Healthy Vimentin
+
 [52] 
Blood Healthy Vimentin
+
 [106] 
Appendix Appendicitis Desmin
+
 [118] 
Breast Carcinoma Vimentin
+
 [119] 
Endothelial Intervillous space Healthy 
CD34
+
CD31
+
 and 
CD34
+
vWF
+
 
[107] 
Trophoblasts Lungs Preeclampsia 
Multi-nucleated giant 
cells 
[22] 
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4. Long-term consequences of fetal microchimerism: association with (non) – 
autoimmune diseases 
As fetal microchimerism in peripheral blood is an almost universal finding during pregnancy 
[29,37,120] and postpartum [27,51], presence of fetal microchimeric cells in the circulation does not 
indicate an aberrant immune response by the mother. However, fetal microchimerism can persist 
more than 27 years [29]. Therefore, it is possible that fetal cells themselves play an active role in 
determining the immune repertoire. The presence of fetal microchimeric cells has been associated 
with later-life disease risk [12,28,29,50,120-123]. Increased fetal microchimerism is associated with 
some autoimmune disease [51]; while decreased fetal microchimerism is found in other malignancies 
[124,125]. Such associations may indicate the ability of fetal microchimeric cells of having allo-
autoimmune or allosurveillance functions [48,126]. The effect of microchimeric cells on the maternal 
immune system and disease status remains unclear [127].  
Fetal microchimeric cells have been associated with several (non-)autoimmune diseases.   
4.1. Pregnancy-associated diseases 
During pregnancy, microchimerism has been associated with polymorphic eruptions of pregnancy 
(PEP), a transient skin disease. These cutaneous eruptions occur in the third trimester of pregnancy 
and usually improve quite spontaneously after delivery. Male DNA was detected in 6 of 10 dermis or 
epidermis samples of women with PEP, whereas no fetal DNA was observed in the 26 controls [38].  
4.2. Non-autoimmune diseases 
The role of microchimeric cells in non-autoimmune disorders, such as hepatitis C, multinodular 
thyroid goiter, melanoma, cervical, lung and breast cancer is still controversial 
[76,115,116,119,125,128-130]. It has been speculated that the presence of these foreign cells in 
tissues might be the consequence rather than the cause of disease, and that they might provide a 
source of progenitor cells, participating in maternal tissue repair processes [115,131]. Others have 
suggested a role in protection by providing immunosurveillance as fetal microchimerism might 
contribute to reduce the risk to develop breast cancer [125,132]. However, a role in disease 
progression has also been considered as fetal microchimeric cells contributed to lymphangiogenesis 
or tumor growth in melanoma [129,132]. 
As breast cancer is less prevalent in parous women compared to nulliparous women, fetal 
microchimeric cells may reduce the risk of developing breast cancer by providing immune 
surveillance in blood. Fetal microchimeric DNA was less prevalent in peripheral blood of women with 
breast cancer than in healthy women. Fetal cells could migrate to the tumor site leading to reduced 
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numbers in peripheral blood [125]. According to Dubernard et al. [119], fetal cells are recruited from 
the peripheral blood into the damaged tissue to repair it if malignancies are developed during 
pregnancy. Compared to healthy controls, less fetal microchimeric cells were also observed in blood 
of patients with cervical cancer [54] or papillary thyroid cancer (PTC) [76,130]. These findings support 
the hypothesis that fetal microchimeric cells reside in maternal niches and can be recruited to the 
site of damaged tissues, where they could differentiate to regenerate the damaged tissue [133].  
4.3. Autoimmune diseases 
In 1996, Nelson postulated that some autoimmune disorders which were commonly seen in middle-
aged women and had similarities with graft-versus-host disease (GvHD) occurring after 
hematopoietic cell transplantation, may in fact be allo-autoimmune diseases caused by fetal 
microchimeric cells [12]. Accumulating evidence suggests that fetal immune cells may be reactive to 
maternal antigens and therefore have the capacity to trigger graft-versus-host reactions (GvHR) [134]. 
This would provide a mechanism for the initiation and/or exacerbation of autoimmune disease. 
Fetal microchimerism has been mainly described in patients with systemic sclerosis, Sjögren’s 
syndrome, systemic lupus erythematosus and primary biliary syndrome. 
4.3.1. Systemic sclerosis 
The first direct discovery of fetal cells in autoimmune diseases was in patients with systemic sclerosis 
(SSc). SSc is an autoimmune skin disease which affects vascular and connective tissues [135]. The 
disease is 3 – 11.8 times more frequent in women than in men, has a peak incidence in women of 
post reproductive age and has striking clinical similarity to GvHD [136]. Skin, lung and esophageal 
involvement is prominent in both diseases, and both are characterized by lymphocytic infiltration of 
affected tissues, up-regulation of inflammatory cytokines and fibrosis of the dermis and visceral 
organs [100,136].  
Fetal DNA and fetal cells were not only identified in peripheral blood and in inflammatory skin lesions 
of some women with SSc [12,51,134,136], but also in their salivary glands [137], spleen, lymph nodes, 
lung and adrenal gland [138]. Although Ohtsuka et al. [59] failed to find any difference in the 
frequency of women carrying male cells, the mean number of microchimeric cells was significantly 
higher in patients with SSc compared to healthy controls [51]. HLA compatibility was more common 
among patients with SSc compared to controls [51,65]. These results led the authors to hypothesize 
that in some cases the fetal cells may have crossed the placental barrier and remained unrecognized 
due to this HLA compatibility [138]. 
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Fetal microchimeric cells expressed CD3 [136] and CD4 [55] and may react against maternal antigens 
[134], supporting the idea that immune responses from fetal cells may contribute to the 
pathogenesis of SSc [51,80,134]. Functional studies provide additional support for a role in disease 
pathogenesis, as CD28 stimulation of PBMCs of patients with SSc caused an increase in the amount 
of fetal microchimeric cells [139]. 
4.3.2. Sjögren syndrome 
Sjögren syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the 
exocrine glands, including salivary and lacrimal glands, with systemic production of autoantibodies 
[137,140]. The pathogenesis of SS remains unclear. SS affects women more frequently, with a 
female-to-male ratio of 4-20: 1 and with the highest incidence in women older than 40 years. SS 
shows clinical and pathologic features resembling those of GvHD [137]. However, results of fetal 
microchimerism in SS are conflicting. Some studies report an increase in salivary glands of patients 
with SS compared to healthy controls [141,142], while other studies did not find any microchimeric 
cells in their glands [137,143]. 
4.3.3. Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease characterized by 
autoreactive cells and autoantibodies, which can potentially affect all organ systems [144]. SLE 
occurs in women and men at a ratio of 7,4 – 10: 1 [145]. Investigation of fetal microchimeric cells in 
SLE has also yielded mixed results [142,144-146]. Patients with SLE had less frequently detectable 
microchimerism compared to healthy controls (0 % versus 20%) [142], while Johnson et al. [145] 
reported the case of a woman with SLE with high numbers of microchimeric cells in her clinically 
affected tissues. Microchimeric cells were detected in the maternal circulation [147,148], and in 
several tissues including intestines and lungs [145]. Renal biopsies of female patients with nephritis 
had significantly more male cells than controls [144]. 
4.3.4. Primary biliary cirrhosis 
Primary biliary cirrhosis (PBC) is an autoimmune disease of unknown etiology leading to progressive 
destruction of small intrahepatic bile ducts by infiltrating immune cells and eventually to liver 
cirrhosis and failure. The disease is characterized by female predominance (7.8 - 16: 1 female: male) 
and is more commonly observed between the ages of 40 and 60 years [140,149]. It has many 
histological similarities with hepatic chronic GvHD [80].  
The initial reports found that the majority of women with PBC had male DNA in their livers, but 
neither the frequency nor the quantity of male DNA differed significantly between healthy controls 
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and patients with other types of liver disease [149,150]. One subsequent report described more fetal 
microchimeric cells expressing CD45 in patients with PBC compared to controls. It was suggested that 
these male fetal cells functioned as antigen presenting cell (APC), triggering an autoimmune 
response to maternal tissues [151]. In the study of Stevens et al. [90], fetal microchimeric cells 
resembled hepatocytes and expressed a surface marker for hepatocytes In liver biopsies of women 
with PBC. 
4.3.5. Autoimmune thyroid diseases 
The main goal of this thesis was to investigate the role of fetal microchimeric cells in autoimmune 
thyroid diseases, which will be discussed in the following chapters. 
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Autoimmune thyroid diseases (AITDs) are the most prevalent autoimmune disorders affecting up to 5% 
of the general population [1,2], with the two most common forms being Graves’ disease (GD) and 
Hashimoto’s thyroiditis (HT). 
Although HT and GD are multifactorial diseases where genes and environmental factors influence the 
onset and development of the disease [3] (Chapter 3), fetal microchimeric cells have been proposed 
to play a functional role in the pathogenesis of AITD. AITD has a marked female predilection and is 
often detected in the years following parturition [4-6]. Fetal microchimeric cells have already been 
described in AITD, but the exact role of these fetal cells remains unknown [7]. 
The main focus of this PhD thesis was to investigate the potential role of fetal microchimeric cells in 
patients with HT or GD by examining their blood. In collaboration with the department of 
endocrinology of UZ Ghent and VUB, blood samples of patients with an AITD were obtained. 
In the following chapter (Chapter 3), an introduction to autoimmune thyroid diseases is given. 
Several genetic and environmental susceptibility factors in the pathogenesis of AITD are described. 
Fetal microchimerism has been investigated in blood of women with HT and GD (Chapter 4). By using 
FISH and immunocytochemistry, male fetal cells could be identified in patients and in healthy 
controls, and the male fetal cell type was determined.   
Several hypotheses have been proposed to point out the functional role of fetal cells in several 
autoimmune and non-autoimmune diseases, being harmful, beneficial or innocent for the mother. In 
Chapter 5, a discussion concerning the potential harmful, beneficial or innocent role of these fetal 
microchimeric cells in autoimmune thyroid diseases is described. 
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1. Autoimmune thyroid diseases 
The thyroid gland (Figure 1) is a major endocrine gland controlling diverse metabolic pathways by 
producing hormones necessary for appropriate energy levels and an active life. These hormones play 
critical roles in early brain development, somatic growth, bone maturation, and mRNA synthesis of 
more than 100 proteins that constantly regulate each and every function in the body [1,2]. 
 
Figure 1: Position of the thyroid gland 
(http://www.yalemedicalgroup.org/stw/Page.asp?PageID=STW023081). 
At the same time, the thyroid is highly vulnerable to autoimmune diseases due to the complexity of 
hormonal synthesis, tyrosine, iodine and selenium requirements for hormonal synthesis and function, 
and the specific capabilities of the thyroid cell to interact with the immune system by producing a 
variety of immunologically active factors [1,3]. Autoimmune thyroid diseases (AITDs) are therefore 
one of the most common autoimmune disorders. AITD occur when the immune system fails to obtain 
tolerance to thyroid autoantigens. The main autoantigens are thyroglobulin (Tg), which has a 
function in thyroid hormone storage, thyroid peroxidase (TPO), the primary enzyme involved in 
thyroid hormonogenesis, and the thyroid stimulating hormone receptor (TSHR). Autoimmunity to the 
thyroid gland results in thyroid hyperfunction or hypofunction [4]. This PhD thesis focused on 
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), the two most common forms that respectively 
lead to hypo- or hyperfunction [5]. Both conditions are characterized by lymphocytic infiltration of 
the thyroid parenchyma [6,7]. 
1.1. Graves’ disease 
Hyperthyroidism is caused by Graves’ disease (GD) in 50 to 80% of the cases. The peak incidence is 
between 40 and 60 years of age [8]. Patients have a palpable, symmetric, smooth, and nontender 
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toxic goiter. In 30 to 50% of the patients, GD is associated with ophthalmopathy [8-10]. The most 
frequent signals of ophthalmopathy are eyelid retraction, periorbital edema, inflammation of the 
extraocular muscles and increase in orbital connective tissue and fat [10,11] (Figure 2). 
 
Figure 2: Clinical manifestations of Graves’ disease.   
Panel A shows diffuse goiter, panels B and C ophthalmopathy [10]. 
Symptoms of GD include nervousness, fatigue, weight loss, heat intolerance, difficulty sleeping, 
tremor, increased frequency of defecation, proximal-muscle weakness, irritability, and menstrual 
irregularity. Patients show stare, eyelid lag, tachycardia, proptosis, goiter, resting tremor, 
hyperreflexia, and warm, moist, and smooth skin [8,10]. 
GD is characterized by the presence of circulating autoantibodies that bind and activate the TSHR, 
stimulating follicular hypertrophy and hyperplasia and causing thyroid enlargement. Moreover, these 
autoantibodies lead to increases in thyroid hormone production resulting in hyperthyroidism [11-13]. 
Thyroid-function testing in GD typically reveals a suppressed serum thyroid stimulating hormone  
(TSH) level and elevated levels of serum thyroxine (T4) and triiodothyronine (T3) [10]. These patients 
can also have autoantibodies to Tg and/or TPO [8].  
Current treatments for Graves’ hyperthyroidism consist of antithyroid drugs, radioactive iodine, 
and/or partial thyroidectomy [10]. Antithyroid drugs, commonly used as initial therapy, can inhibit 
thyroid hormone synthesis. Radioiodine therapy may be used either as initial therapy or after 
treatment with medication in order to induce hypothyroidism to prevent a recurrence of GD. 
Subtotal thyroidectomy is preferred for patients with Graves’ hyperthyroidism, especially those with 
a large goiter. It can be effective in patients with complications of antithyroid drugs, pregnant 
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women requiring high doses of antithyroid drugs, patients who decline treatment with radioiodine or 
who have large goiters or suspicious nodules [8,10]. 
The autoimmune process that leads to GD is believed to begin with the activation of thyroid-specific 
CD4
+
 T cells, with subsequent recruitment of autoreactive B cells into the thyroid and production of 
anti-thyroid antibodies [14,15] (Figure 3). 
 
 
Figure 3: In Graves' disease, activated CD4
+
 T cells induce B cells to secrete thyroid-stimulating 
immunoglobulins (TSI) against the TSHR, resulting in increased thyroid hormone production and 
hyperthyroidism [14]. 
1.2. Hashimoto’s thyroiditis 
Hashimoto’s thyroiditis (HT) is the most common cause of hypothyroidism and occurs in 5 to 15% of 
the population [16]. It occurs most frequently in women aged between 30 and 50 years, with women 
comprising nearly 95% of all cases [17-19]. Patients with hypothyroidism may have a goiter (HT) or 
have an atrophic thyroid. Patients with HT can also present with euthyroidism [11,17].  
A goiter usually develops gradually and may be found during routine examination or ultrasonography 
(Figure 4). In rare cases, the thyroid gland enlarges rapidly and the adjacent structures in the neck 
such as the trachea, esophagus, and recurrent laryngeal nerves, may be compressed. However, these 
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findings might also raise suspicion of thyroid lymphoma or carcinoma, particularly in elder patients 
[17].  
 
Figure 4: Enlargement of the thyroid can expand the gland well beyond  
its normal size (outline) and cause a noticeable bulge in the neck  
(http://www.mayoclinic.org/enlarged-thyroid/IMG-20005923). 
HT results in impaired thyroid hormone production and clinical hypothyroidism, resulting in reduced 
metabolic activity in various cells and tissues. Most occurring symptoms associated with HT include 
weight gain, depression, difficulty in concentrating, cold intolerance, constipation, chronic fatigue, 
muscle weakness, bradycardia, migraines, memory loss, infertility and hair loss [12]. 
HT is characterized by diffuse lymphocytic infiltration, thyroid follicles of reduced size containing 
sparse colloid, and fibrosis replacing the thyroid parenchyma [12]. Specific autoantibodies in serum, 
including anti-TPO antibodies and anti-Tg antibodies are present. Thyroid ultrasonograms are useful 
for measuring thyroid size and assessing thyroid echo texture. Hypo-echogenicity of the thyroid may 
suggest severe follicular degeneration [17].  
Initiation of the autoimmune reaction in HT by autoreactive CD4
+
 T cells results in a massive 
lymphocyte accumulation in the thyroid gland. Activated CD8
+
 and CD4
+
 T cells, B cells, plasma cells 
and macrophages constitute the immunocyte infiltrate. Thyroid autoantibodies have been proposed 
to participate in hypothyroidism by blocking the TSHR. Activated CD8
+
 T cells could be responsible for 
thyrocyte destruction [14] (Figure 5).  
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Figure 5: During Hashimoto's thyroiditis, self-reactive CD4
+
 T cells recruit B cells and CD8
+
 T cells into the 
thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and 
thyroid-specific cytotoxic T lymphocytes (CTL) have been proposed to be responsible for autoimmune thyrocyte 
depletion [14]. 
2. Susceptibility factors for AITD 
The etiology of AITD and the mechanisms leading to either HT or GD are unknown. However, AITD 
are complex diseases, caused by an interaction between susceptibility genes and non-genetic factors 
[7,20]. 
2.1. Genetic factors 
HT and GD are both characterized by lymphocytic infiltrates reactive against thyroid antigens and the 
production of thyroid-specific autoantibodies. Genes specific to either HT or GD could explain the 
different pathways that the two diseases ultimately follow: the hallmark of GD is the production of 
TSHR stimulating antibodies causing hyperthyroidism, whereas HT is characterized by thyrocyte 
apoptosis, leading to glandular destruction and ultimately clinical hypothyroidism [21].  
The importance of genetic factors in AITD susceptibility is supported by familial clustering, variable 
prevalence in different ethnic groups, associations with HLA haplotypes or single nucleotide 
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polymorphisms, and concordance rates in monozygotic and dizygotic twins [11,22]. In addition, 
population-based case-control studies, linkage analysis, and genome screens have identified several 
potential susceptibility genes for AITD [23,24].  
The major identified AITD susceptibility genes are the HLA genes. HLA DRB1*03, DQA1*0501 and to a 
lesser extent DQB1*02, together making up the DR3 susceptibility haplotype, are strongly associated 
with GD [25-27] while HLA-DR5 is associated with HT [12,28]. DRB1*07 was negatively associated 
with GD, and was suggested to be protective [29,30]. Other susceptibility genes are immune 
regulatory genes such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), CD40 and protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) [7,21,24,28,31]. Obvious candidate genes for 
AITD are the thyroid-specific genes such as the Tg gene and TSHR gene [7,21,24,28,31]. Sequencing 
of the entire Tg coding sequence revealed 4 SNPs that were significantly associated with AITD [19]. 
TSHR is distributed in the thyroid, lymphocytes, fibroblasts, and adipocytes. TSHR-stimulating 
antibodies bind to the TSHR, activate adenylate cyclase, increase the rate of thyroid hormone 
synthesis and secretion, induce thyroid growth, and increase vascularity. Nearly all patients with GD 
and some patients with HT express autoantibodies against the TSHR [11]. All associated TSHR SNPs 
are intronic. It remains to be determined how the intronic SNPs in the TSHR gene could predispose to 
GD [19].  
It is possible that multiple gene polymorphisms are required to develop AITD as no strong 
associations of susceptibility genes with AITD have been reported. However, even in a genetically 
predisposed person, a triggering event is usually required for autoreactivity [20]. 
2.2. Non-genetic factors 
While the exact etiology of thyroid autoimmunity is unknown, it is believed to develop when a 
combination of genetic factors and non-genetic (environmental and hormonal) events leads to 
breakdown of tolerance. Iodine, low selenium, bacterial or viral infection, stress, smoking and drugs 
such as lithium can damage the thyrocytes [28,32].  
Iodine is required for the synthesis of the two thyroid hormones T4 and T3. It may alter the 
antigenicity of Tg, forming toxic metabolites and damaging thyrocytes. In addition, iodine may 
generate oxygen free radicals within the thyroid, leading to direct cellular toxicity [11]. Selenium, 
acting as an antioxidant by reducing free radical formation, is an essential trace element that plays an 
important role in thyroid hormone synthesis. Low selenium can cause enlargement of the thyroid 
gland and thyroid hypo-echogenicity, which is a marker for lymphocyte infiltration [32]. Drugs such 
as lithium which have a direct inhibiting effect on the release of thyroid hormones, can also be a 
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trigger for AITD. Lithium-induced increases in serum TSH concentrations might enhance autoantigen 
expression at the surface of thyrocytes, thereby exacerbating autoimmune responses [1,32].  
Bacterial or viral infection might represent a risk factor for development of AITD. Potential 
mechanisms of infectious triggers include cell damage with release of autoantigens, expression of 
new antigens, and molecular mimicry due to sequence similarities between bacterial or viral antigens 
and self-antigens [11]. Yersina enterocolitica infection has been linked with GD through molecular 
mimicry [6] as it has a hormone-specific binding site for the mammalian TSH that resembles the TSHR 
in the human thyroid gland [1]. An immune response against a viral antigen that shares homology 
with the TSHR may be the inductive event that ultimately leads to TSHR autoimmunity [13]. However, 
the role of infection is only weakly supported [20,33]. Stressful major life events have also been 
linked to the precipitation of AITD, particularly GD. The pathophysiologic mechanism behind the 
influence of such events on the autoimmune process is unclear, but could be related to alterations in 
the hypothalamic-pituitary adrenal axis that occur during and after the events, resulting in overall 
immune suppression [11]. Smoking is a risk factor for Graves’ hyperthyroidism and an even stronger 
risk factor for Graves’ ophtalmopathy [1,6,32,34], and has been associated with HT as well. However, 
the mechanism behind it remains unclear [1,11,32]. 
2.3. Fetal microchimerism 
Although HT and GD are multifactorial diseases where genes and environmental factors influence the 
onset and development of the disease [1,35], fetal microchimeric cells, which could become 
activated in the postpartum period once the maternal immune suppression is lost, have been 
proposed to play a functional role in the pathogenesis of HT and GD [36-43]. 
In the following chapters, blood of patients with an AITD was analyzed for the presence of male fetal 
microchimerism (Chapter 4) and the potential role of fetal microchimerism in AITD is discussed 
(Chapter 5).    
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Abstract 
 
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), two autoimmune thyroid diseases (AITD), 
occur more frequently in women than in men and show an increased incidence in the years following 
parturition. Persisting fetal cells could play a role in the development of these diseases.  
Aim of this study was to detect and characterize male fetal cells in blood of postpartum women with 
and without an AITD. Eleven patients with an AITD and ten healthy volunteers, all given birth to a son 
maximum 5 years before analysis, and three women who never had been pregnant, were included. 
None of them had any other disease of the thyroid which could interfere with the results obtained.  
Fluorescence in situ hybridization (FISH) and repeated FISH were used to count the number of male 
fetal cells. Furthermore, the male fetal cells were further characterized.  
In patients with HT, 7 to 11 male fetal cells per 1.000.000 maternal cells were detected, compared to 
14 to 29 male fetal cells in patients with GD (p = 0.0061). In patients with HT, mainly male fetal CD8+ 
T cells were found, while in patients with GD, male fetal B and CD4+ T cells were detected. In healthy 
volunteers with son, 0 to 5 male fetal cells were observed, which was significantly less than the 
number observed in patients (p < 0.05). In women who never had been pregnant, no male cells were 
detected. 
This study shows a clear association between fetal microchimeric cells and autoimmune thyroid 
diseases. 
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Introduction 
 
Autoimmune diseases affect approximately 5-8% of the population and of all the subjects with an 
autoimmune disease, 78% are women [1]. Many hypotheses have been proposed to explain this 
gender bias: differences in cytokine and hormone production in men and women, and/or differences 
in the degree of immune response which tends to be more vigorous in females, resulting in a higher 
antibody production and cell-mediated immunity after immunization [2].  
Another explanation might be found in the postpartum presence of fetal cells in the maternal 
circulation and tissues. During pregnancy, fetal cells cross the placenta into the maternal circulation 
[3,4]. The immunological interaction between maternal and fetal immune cells should at that point 
be minimal or negligible [5]. Fetal cells can persist in the postpartum period, which indicates 
insufficient elimination after delivery [6]. These cells reside in maternal blood and tissues such as the 
skin and the thyroid [7-11]: the mother becomes microchimeric. The persistence of fetal cells may 
result in the development of autoimmune diseases that affect women postpartum, such as 
autoimmune thyroid diseases (AITDs) [12,13]. This assumption is based on the higher incidence of 
these diseases in women in the decades that follow parturition [13,14].  
Autoimmune thyroiditis and Graves’ disease are two autoimmune thyroid diseases, affecting 5-15% 
of women. In patients with autoimmune thyroiditis, specific auto-antibodies in serum are present, 
including anti-thyroid peroxidase antibodies (TPOAb), anti-thyroglobulin antibodies (TgAb) and 
autoantibodies binding to the TSH receptor (TSHRAb). Patients with hypothyroidism and goiter have 
Hashimoto’s thyroiditis (HT). A variant of HT is atrophic thyroiditis. These patients present with  
hypothyroidism and atrophic thyroid [15]. Patients with HT can also present with euthyroidism. 
Graves’ disease (GD) is characterized by the presence of circulating autoantibodies that bind and 
activate the thyrotropine receptor (TSHRAb), stimulating follicular hypertrophy and increases in 
thyroid hormone production resulting in hyperthyroidism [16,17]. These patients can also have TgAb 
and/or TPOAb [18].  
HT and GD are more prevalent in women between the ages of 30 and 50 years, with a ratio 
female:male of respectively 10:1 and 7:1, and are often detected in the years following parturition 
[17,19,20]. Therefore, our study focused on these two autoimmune thyroid diseases. 
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It has been hypothesized that within the thyroid, the presence of fetal cells may initiate an immune 
response resulting in AITD [5,19]. However, direct evidence for such an effect is lacking. To our 
knowledge, no studies have examined which fetal cell types are present in blood of patients with HT 
and GD. The aim of this study was to compare the amount of male fetal microchimeric cells in 
peripheral blood of women with and without an autoimmune thyroid disease and to characterize the 
detected male fetal cells.  
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Materials and methods 
Ethics Statement 
This study was approved by the Ethics Committee of the Ghent University (B67020095877), Belgium, 
and written informed consent was obtained from all participants. 
Study participants 
The diagnosis of Hashimoto’s thyroiditis was based on the presence of thyroid antibodies (TgAb, 
TPOAb) and hypothyroidism. The diagnosis of Graves’ disease was based on the presence of 
hyperthyroidism, diffuse goiter, and positive serum TSH receptor antibodies. Peripheral blood (PB) 
was collected from 11 patients with an AITD, who had given birth to a son maximum five years 
before analysis. Blood was also obtained from 10 healthy volunteers who had given birth to a son 
maximum five years before analysis and from 3 women who never had been pregnant nor had a 
transfusion or transplantation. In addition, PB was collected from two women who were pregnant 
during the course of the study. Peripheral blood was taken just before birth of their son, 1 week and 
6 months postpartum. Extreme precautions were taken to avoid external contamination. In 
particular, all samples were handled by a female laboratory technician.  
Fluorescence in situ hybridization (FISH) 
Peripheral blood mononuclear cells (PBMCs) were isolated from the patient’s EDTA blood samples by 
density gradient centrifugation on Ficoll-Paque Plus (GE Healthcare, Diegem, Belgium) according to 
the manufacturer’s instructions. From each sample, 1.000.000 PBMCs were cytospun on 4 glass 
slides as previously described [21]. The slides were air dried and fixed for 5 minutes in a Carnoy’s 
fixative (3:1 methanol (Fisher scientific, Leicestershire, UK): acetic acid (Sigma-Aldrich, Bornem, 
Belgium)).  
Male fetal cells were distinguished from maternal cells by fluorescence in situ hybridization (FISH) 
with CEP X SpectrumOrange/CEP Y SpectrumGreen DNA probes (Vysis, Abbott Molecular, Illinois, US). 
Male cells showed one SpectrumGreen Y FISH dot and one SpectrumOrange X-FISH dot, while female 
cells contained two SpectrumOrange X FISH dots (Figure 1).  
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Figure 1. FISH and Repeated FISH: A. FISH of female cells, showing two SpectrumOrange X FISH spots and of a 
presumed male cell indicated by an arrow, showing one SpectrumOrange X FISH and one SpectrumGreen Y 
FISH spot; B. Repeated FISH of the female cells and the presumed male cell, showing no SpectrumAqua Y FISH 
spots in the female cells. In contrary, the male cell shows one SpectrumAqua Y FISH signal on the exact same 
location as the SpectrumGreen Y FISH spot in image A (indicated by an arrow), indicating this is a true male cell. 
C. FISH of female cells and of one presumed male cell, indicated by an arrow. D. Repeated FISH of a male cell (C) 
shows no SpectrumAqua Y FISH spot. The SpectrumGreen Y FISH spot was probably caused by cellular debris or 
dust particles. The SpectrumOrange X FISH spot of that cell is more diffuse than the other SpectrumOrange 
spots which may indicate two SpectrumOrange X FISH spots lying very closely to each other.  
 
FISH was performed following the manufacturer’s instructions with minor adjustments. Samples 
were incubated in a 0.01% pepsin (Serva Electrophoresis, Heidelberg, Germany)/0.01M HCl (Sigma-
Aldrich)-solution during 30 min at 37°C and washed with PBS (Invitrogen, Paisley, UK) and washing 
buffer (1x PBS, 0.5M MgCl2 (Sigma-Aldrich)). In the next step, cells were fixed for 10 min in 1% 
formaldehyde (Acros Organics, Geel, Belgium), rinsed with PBS, dehydrated for 3 min using an 
ethanol series (70%, 90% and 99%, Merck, Darmstadt, Germany) and air-dried. Afterwards, DNA was 
denatured by heating the slides in a denaturation solution (70% formamide (Sigma-Aldrich), 2x SSC 
(Vysis)) for 5 min at 73°C. Slides were dehydrated again for 1 min using an ethanol series (70%, 90% 
and 99%). Slides were dried on a hot plate (50°C) and 5µl of the pre-denatured probe-mixture was 
added on each slide. After applying a coverslip, hybridization was performed at 42°C overnight. 
Subsequently, slides were rinsed for 5 min with preheated 0.4x SSC/0.1% NP-40 (Sigma-Aldrich) 
solution at 73°C and three times for 2 min at room temperature (RT) with 2x SSC/0.1% NP-40. After 
air-drying, the slides were mounted with antifade Vectashield mounting solution (Vector Labs, 
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Burlingame, CA, USA) containing 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI, 400 ng/ml, 
Sigma-Aldrich) to counterstain all nuclei on the slide. A coverslip was applied.  
Fluorescence scanning 
The scanning stage was controlled by the AxioVision 4.6.3 software (Carl Zeiss, München, Germany), 
using the MosaiX module. Image acquisition was carried out with the AxioVision multichannel 
fluorescence module and the AxioCam MRm camera (Carl Zeiss). Cell nuclei were visualized using 
Zeiss filter set no. 49 (G 365 nm, FT 395, BP 445/50), Y chromosome spots with Zeiss filter set no. 38 
(BP 470/40, FT 495, BP 525/50) and X chromosome spots with filter set no. 20 (BP 546/12, FT 560, BP 
575-640). Slides were scanned at 20x magnification using a Carl Zeiss short distance Plan-
Apochromat® objective [21]. From every slide, 582 images were acquired and were stored as 
separate tiff-files.  
Segmentation and masking 
For automatic detection of the male fetal cells, the image processing AxioVision Commander module 
(Carl Zeiss) was used. All steps of processing, analysis, and evaluation were stored in an AxioVision 
Commander Script, which could be run automatically on the stored images. This script was based on 
previously published scripts with some specific modifications (Figure 2) [21,22]. SpectrumOrange X 
chromosome FISH signals were used as a visual control. The validation of the script has been 
described earlier [21].  
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Figure 2. AxioVision Commander script for the automatic detection of male fetal cells: A. Original image, split 
up in B. DAPI image and C. SpectrumGreen image; D. Threshold interactive on the DAPI image: segmentation 
based on the definition of a brightness range. Pixels within the defined gray level range are set to the maximum 
gray value 1 (pseudocolor blue); whilst pixels outside it are set to the minimum gray value 0 (black), resulting in 
a binary image; E. Scrap of image D: removing all artefacts too small to be possibly originating from cell nuclei; 
F. Close: filling in gaps in the contours of the nuclei; G. Dynamic Threshold of the SpectrumGreen image, 
resulting in a binary image showing the Y chromosome FISH spots; H. Scrap of image G: all regions smaller than 
10 pixels and larger than 65 pixels are removed; I. Masking of the binary images F and H: retaining only the 
SpectrumGreen FISH signals lying in a nucleus. In the last step, to be included as a true FISH signal, the detected 
regions had to fulfil four measurement parameter conditions with regard to area of the region, lowest and 
highest pixel density (fluorescence intensity/area²) and standard deviation of the pixel density (not shown). 
 
Repeated FISH 
Results of FISH were confirmed using another CEP Y FISH probe labelled with SpectrumAqua (Vysis). 
The repeated FISH protocol was performed as described by Liu et al. with a few minor modifications 
[23]. Cover slips applied after FISH were washed off in water. Slides were incubated for 10 min in 
respectively 60% formamide/2x SSC solution; 2x SSC and 4x SSC/0.1% NP-40 solution at 50°C. Slides 
were dehydrated for 1 min through an ethanol series (70%, 90% and 99%) at RT and air-dried. 
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Denaturation, hybridization and subsequent washing steps were performed as described above. 
Results of the repeated FISH were visualized by using the Zeiss filter set no. 47 (BP 436/20, FT 455, BP 
480/40) (Figure 1 B).  
Phenotyping of the fetal microchimeric cells 
For 6 patients with an AITD, phenotyping of the male fetal microchimeric cells was performed. After 
isolation of the PBMCs, B, CD4+ T and CD8+ T cells were enriched using an EasySep positive selection 
strategy (Stemcell Technologies, Vancouver, Canada) according to manufacturer’s instructions. These 
cell fractions were cytospun on poly-L-lysine slides and underwent FISH and repeated FISH as 
described above. Purity of the different isolated fractions was determined by flow cytometry. Cells 
were stained with monoclonal antibodies against CD3 (labelled with PE-Cy5; 1:20), CD4 (FITC; 1:20), 
CD8 (PE-Cy7; 1:20) and CD19 (PE; 1:20) (eBiosciences) for 30 min on ice, in the dark [24]. All analyses 
were performed on a Cytomics FC500 flow cytometer (Beckman Coulter, Miami, Florida, US) and 
data analysis was performed by CXP analysis software (Beckman Coulter).  
Statistical analysis 
Levels of significance were calculated by SPSS (IBM, New York, US) using Mann Withney (MW) test. p 
< 0.05 was regarded as significant.  
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Results 
Study participants 
A medical history concerning former pregnancies, transplantations and blood transfusions, which can 
influence the results of microchimerism, was available for patients (Table 1) and healthy volunteers 
(Table 2). Patients with an AITD and healthy volunteers, both with a son, were of similar age (mean 
32.1 yr (range 25-37) for patients and mean 31.1 yr (range 26-39) for healthy volunteers; p = 0.41). 
Three healthy volunteers who never were pregnant and two healthy volunteers who were pregnant 
at the conduct of the study, were younger (mean 26.4 yr (range 25-27 yr); p = 0.015). Patients and 
healthy volunteers with son, had similar numbers of children (mean 1.4 (1-2) versus 1.5 (1-2); p = 
0.69) and similar number of boys (mean 1 versus 1.2 (1-2)); which were of similar ages (mean 32.4 
months (10-68 months) versus 36.3 months (3-91 months); p = 0.85). None of the patients and 
healthy volunteers had any other disease of the thyroid. There was no significant difference in the 
amount of isolated PBMCs/ml PB between patients and healthy volunteers (data not shown). 
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Table 1: Patients’ information possibly relevant to fetal microchimerism (*within the conduct of the 
study) 
Patient AITD Age 
patient 
(years) 
Diagnosis 
since birth 
of 
youngest 
son 
(months) 
Age 
(months)
*
 
and sexes 
of the 
children 
Miscarriage Transfusion Additional 
information 
considering 
the thyroid 
Male 
fetal 
cells/ 
1.000.000 
maternal 
cells 
1 HT 32 10 10; male - - - 11 
3 HT 35 12 39; male, 
16; 
female 
3 x very early 
in pregnancy 
- Aunt with 
thyroid 
dysfunctions 
8 
5 HT 25 8 16; male - - - 8 
6 HT 35 3 51; male, 
87; 
female 
5 yrs ago - - 7 
7 HT 36 4 26; male - - Mother with 
hypothyroid 
7 
9 HT 29 unknown 15; male - - - 9 
11 HT 32 unknown 18; male 2 x, 1 and 3 
years ago 
- Mother and 
grandmother 
with 
hypothyroid 
10 
         
2 GD 37 12 37; male 6,5 months 
old death 
born son 4 
yrs ago 
- Aunt with 
hyperthyroid 
29 
4 GD 32 4 25; male - 9 yrs ago - 15 
8 GD 32 unknown 68; male, 
8; female 
- - - 14 
10 GD 28 5 37; male, 
123; 
female 
- - - 21 
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Table 2: Healthy volunteers’ information possibly relevant to fetal microchimerism. 
Healthy 
Volunteer 
Age  
volunteer 
(years) 
Age (months)
*
 and 
sexes of the 
children 
Miscarriage Transfusion Additional information 
considering the 
thyroid 
Male fetal cells 
/1.000.000 
maternal cells 
1 31 43; male 1.5 yr ago at 7 
weeks 
- - 3 
2 39 91; male, 59; male - - - 3 
3 34 45; male, 20; male - - Sister with possibly GD 3 
4 26 6; male - - - 1 
5 29 54; male - - - 1 
6 29 33; male, 7; female 17m ago - - 1 
7 32 32; male, 68; 
female 
- - - 5 
8 31 50; male, 89; 
female 
- - - 1 
9 33 3; male 2x; 2 and 1 yr 
ago 
- - 0 
10 27 6; male - - - 1 
Pregnant 1, 1 week 
before delivery 
27 - - - - 2 
Pregnant 1, 1 week 
postpartum 
27 0; male - - - 2 
Pregnant 1, 6 
months 
postpartum 
28 6; male - - - 1 
Pregnant 2, 1 week 
before delivery 
26 - - - - 1 
Pregnant 2, 1 week 
postpartum 
26 0; male - - - 1 
Pregnant 2, 6 
months 
postpartum 
26 6; male - - - 1 
Negative control 1, 
never pregnant 
26 - - - - 0 
Negative control 2, 
never pregnant 
25 - - - - 0 
Negative control 3, 
never pregnant 
27 - - - - 0 
*within the conduct of the study 
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Male fetal microchimerism in patients and healthy volunteers  
The number of male fetal cells detected in patients with HT or GD and healthy volunteers is shown in 
Table 1 and 2 respectively. All patients had detectable male fetal microchimerism in their PB, ranging 
from 14 to 29 male fetal cells per million maternal cells for patients with GD and from 7 to 11 male 
fetal cells per million maternal cells for patients with HT. In all healthy volunteers who gave birth to a 
son, except for one, male fetal microchimeric cells were found in PB and ranged from 1 to 5 male 
fetal cells per million maternal cells. There was a statistically significant difference between patients 
with GD and patients with HT compared to healthy controls (respectively p = 0.002 and p = 0.0007, 
MW) (Figure 3). Moreover, patients with GD had significant more male fetal cells in their blood 
compared to patients with HT (MW, p = 0.0061).  
 
Figure 3. Boxplot: Male fetal cells in patients with GD or HT, and healthy volunteers with son: Minimum and 
maximum numbers of detected fetal cells are shown, as well as first quartile, median and third quartile. The 
number of fetal cells was significantly different between the three groups (p <0,05). Moreover, a significant 
difference between patients with GD and patients with HT was observed (MW, p = 0,0061). 
 
Blood obtained from two women pregnant of a boy, contained respectively 2 and 1 male fetal cell(s) 
per million maternal cells. One week postpartum, these women had the same amount of male fetal 
cells in their blood as before delivery (2 respectively 1). Blood was also obtained 6 months 
postpartum and revealed in both women 1 male fetal cell per million maternal cells (Table 2).  
As every woman had given birth to a son, the origin of the male cells is likely to be fetal. However, 
persistent microchimerism occurring after blood transfusion or transplantation has also been 
described [25], and this possibility cannot be ruled out for patient 4 (GD) who had a blood 
transfusion 9 years ago. However, as the results of this patient did not differ from the results of other 
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patients with Graves’ disease, and hence inclusion or exclusion didn’t influence the results, this 
patient was included in our study but results for this specific patient should be interpreted carefully.  
The negative control group, consisting of three women who had never been pregnant nor had a 
transfusion or abortion, was consistently negative for male cells (Table 2). 
Flow cytometry for determination of purity of EasySep isolated cells 
Purity of the EasySep isolated cells was assessed by flow cytometry (Beckman Coulter Cytomic FC 
500). For the isolation of B cells, CD4+ T cells and CD8+ T cells, a purity of respectively 97.6%, 97.4% 
and 94.1% was obtained (data not shown). 
Fetal microchimeric cells in PBMC subsets 
All patients selected for our analysis were positive for male cells in unsorted PBMCs. Table 3 shows 
the distribution of the male fetal cells in the different cell subtypes (CD4+ T, CD8+ T, B cells and other 
cell types) for 6 patients with an AITD (patient 2, 7, 8, 9, 10 and 11). For patient 5, only male fetal T 
cells were detected (9.3 fetal cells per 1 million maternal T cells) and no subdivision into CD4+ and 
CD8+ T cells could be made, due to sample amount limitation. No male fetal B cells or other male 
fetal cell types were detected in this patient (data not shown in Table 3). 
In patients with GD, the majority of the male fetal cells were found in the B cell fraction and CD4+ T 
cell fraction while in patients with HT, male fetal cells were mainly CD8+ cytotoxic T cells.  
Table 3: Male fetal cells in the sorted cell fractions in patients with HT (patient 7, 9 and 11) and GD 
(patient 2, 8 and 10). 
Cell type Pat 7  
(HT) 
Pat 9  
(HT) 
Pat 11  
(HT) 
Pat 2  
(GD) 
Pat 8  
(GD) 
Pat 10  
(GD) 
B cell CD19
+
 0 3.4 1.2 4.0 4.0 9.0 
T cell CD4
+
 0 1.5 1 1.0 2.5 9.7 
 CD8
+
 4.7 6.0 3.4 1.5 0.5 9.3 
Other cell types 0 0 0 0 0 9.3 
Data are represented as normalized counts of male fetal cells per 1 million maternal cells. T cells were split up 
immediately into CD4+ and CD8+ T cells. B and T cells were positively isolated with the EasySep® isolation kits. 
Cells not isolated with T or B cells, formed the cell population ‘other cell types’. B cells were counted in a range 
from 1.000.000 to 2.000.000 cells, CD4
+
 T cells ranged from 1.000.000 to 2.250.000 and CD8
+
 T cells from 
1.500.000 to 2.000.000.   
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Discussion 
Hashimoto’s thyroiditis and Graves’ disease, two autoimmune thyroid diseases, occur more often in 
women than in men and show an increased incidence in the decades that follow parturition 
[10,17,19,20]. It has been hypothesized that fetal microchimeric cells play a role in the pathogenesis 
of these diseases [5,26,27]. Although male fetal microchimerism has already been shown in the 
thyroid glands in 50% of these patients, no studies to date have detected and characterized fetal cells 
in peripheral blood, although blood from these patients is easier to obtain in contrast to thyroid 
tissue [9,11,26,27]. Studies describing the presence of fetal cells in thyroid glands, often do not 
mention the reason of removal of the thyroid gland [9,27]. Srivatsa et al. analysed thyroid glands 
from patients with HT removed because of follicular neoplasm or papillary carcinoma [11]. The 
presence of tumor cells may confound the analysis and the results [9,27,28]. Therefore, only patients 
without any other disease of the thyroid were included in our study. Our study focused only on 
women who had given birth to a son since male fetal cells are easier to detect in contrast to female 
fetal cells. 
To examine the presence of male fetal cells in autoimmune thyroid diseases, blood from female 
patients with GD or HT who had given birth to a son maximum five years before analysis, was 
assessed in this study. Using FISH and repeated FISH as an additional confirmation, the number of 
male fetal cells in patients was compared with that detected in healthy volunteers. All patients with 
an autoimmune thyroid disease included in our study had detectable male fetal microchimerism in 
their blood. This is contrary to results obtained in the thyroid glands where only 50% of the patients 
had male fetal microchimerism. The highest number of male fetal cells was observed in the unsorted 
PBMC fraction of patients with GD (14 to 29 male fetal cells per million maternal cells), followed by 
HT (7 to 11) compared to the low number of male fetal cells detected in healthy volunteers (0 to 5). 
This indicates a higher degree of male fetal microchimerism in AITD compared to healthy controls. 
Moreover, significant more male fetal cells were detected in patients with GD compared to patients 
with HT (p = 0.0061).  
Two additional control groups were included in our study. Analysis of the blood of two pregnant 
women revealed respectively 1 and 2 male fetal cells per million maternal cells. This corresponds to 
the number of male fetal cells detected in our healthy group and the amount detected by Bianchi et 
al. [6]. As a negative control group for this study, blood from women who never were pregnant nor 
had a transfusion or transplantation, was obtained. No male cells were detected in their blood, which 
gives strong evidence of the reliability of the techniques used in our study. 
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As a significant difference in male fetal cells was found between patients with HT and GD, it can be 
presumed that fetal cells have a different role in the pathogenesis of both diseases. Our study 
focused on the presence of male fetal B and T cells because these subsets are more likely to initiate 
or be involved in immune response. In patients with HT, mainly male fetal CD8+ cytotoxic T cells were 
found. In patient 5, only male fetal T cells were detected (9.3 male fetal cells per million maternal 
cells). In patient 7, male fetal cells were only detected in the CD8+ T cell fraction (4.7 male fetal cells 
per million maternal cells). In patient 9 and 11, the majority of male fetal cells was composed of CD8+ 
T cells (respectively 6 and 3,4 male fetal cells per million maternal cells). The remaining male fetal 
cells for these patients consisted of CD4+ T cells (respectively 1.5 and 1 male fetal cell(s) per million 
maternal cells) and B cells (respectively 3.4 and 1.2 male fetal cells per million maternal cells). One 
might speculate that these cytotoxic T cells could cause cell death leading to hypothyroidism [29]. In 
GD however, the majority of male fetal cells was found in the B cell fraction (4 male fetal cells per 
million maternal cells for patient 2 and patient 8). These B cells could possibly be activated by fetal 
CD4+ T cells (1 male fetal cell per million maternal cells and 2.5 male fetal cells per million maternal 
cells respectively for patient 2 and 8). In one patient with GD (patient 10), more male fetal T cells (9.7 
male fetal CD4+ T cells per million maternal cells and 9.3 male fetal CD8+ T cells per million maternal 
cells) than male fetal B cells (9 male fetal cells per million maternal cells) were found, along with 
some other cell types (9.3 male fetal cells per million maternal cells). These other cell types were 
cells not isolated during selection of the T and B cells and are likely to be natural killer (NK) cells or 
hematopoietic progenitor cells capable of differentiating into immune competent cells [30]. One 
might speculate that thyroid-reactive T cells could cause activation of thyrotropin receptor (TSHR)-
reactive B cells, secreting TSHR-stimulating antibodies causing hyperthyroidism [29]. These thyroid 
antibodies have already been described in blood [31].  
Fetal microchimeric cells could play a role in the pathogenesis of AITD in two ways: direct or indirect. 
In a direct manner, fetal lymphoid cells migrating into the thyroid could initiate a graft-versus-host 
reaction against maternal thyroid antigens resulting in an autoimmune thyroid disease [5,13]. On the 
other hand, intrathyroidal fetal cells, not necessarily of the lymphoid lineage, could indirectly be 
involved in the pathogenesis of autoimmune thyroid disease by activating intrathyroidal maternal T 
cells against fetal antigens. Despite the fact that the male fetal cells were only characterized in a 
limited number of patient samples, an increase in male fetal lymphocytes was clearly shown, which 
provides support for the first hypothesis.  
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Conclusion 
In conclusion, our findings indicate a significant difference in number of male fetal cells in the 
maternal circulation of patients with an AITD and healthy volunteers despite similar age, number and 
gender of their children. In addition, a significant difference was found between patients with GD 
and HT, where patients with GD had more male fetal cells in their blood circulation. Moreover, the 
male fetal cells were of a different cell type which might possibly correlate to the pathogenesis of 
both diseases. Our study shows a clear association between male fetal microchimeric cells and 
autoimmune thyroid diseases and indicates the value and need for further research in this field. 
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Abstract 
Autoimmune thyroid diseases (AITD) show a female predominance, with an increased incidence in 
the years following parturition. Fetal microchimerism has been suggested to play a role in the 
pathogenesis of AITD. However, only the presence of fetal microchimeric cells in blood and in the 
thyroid gland of these patients has been proven, but not an actual active role in AITD. Is fetal 
microchimerism harmful for the thyroid gland by initiating a graft-versus-host reaction (GvHR) or 
being the target of a host-versus-graft reaction (HvGR)? Is fetal microchimerism beneficial for the 
thyroid gland by being a part of tissue repair or are fetal cells just innocent bystanders in the process 
of autoimmunity? This review explores every hypothesis concerning the role of fetal microchimerism 
in AITD.  
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Autoimmune Thyroid Diseases 
Autoimmune thyroid diseases (AITDs) are the most prevalent autoimmune disorders affecting up to 
5% of the general population [1,2]. The two most common forms of AITD are Graves’ disease (GD) 
and Hashimoto’s thyroiditis (HT). Although HT and GD are multifactorial diseases where genes and 
environmental factors influence the onset and development of the disease [3], fetal microchimeric 
cells have been proposed to play a functional role in the pathogenesis of HT and GD [4-10]. 
Fetal microchimerism in AITD 
Fetal cells have shown to be more common in thyroid glands [6-10] and in blood [4,9] of patients 
with AITD compared to healthy controls or patients with a benign adenoma or nodular goiter. Results 
of these studies are shown in Table 1.  
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Table 1: Studies describing fetal microchimerism in AITD 
Author 
(Autoimmune) Thyroid Disease or 
Healthy 
Biological material Technique 
% of women positive 
for fetal cells (n/total) 
Number of fetal 
cells/number of maternal 
cells 
Lepez et al. 
[4] 
HT 
Blood FISH and repeated FISH 
100% (7/7) 7-11 /1.000.000 
GD 100% (4/4) 14-29 /1.000.000 
Healthy 90% (9/10) 0-5 /1.000.000 
Renne et al. 
[7] 
HT 
Paraffin-embedded 
thyroid tissue 
FISH 
60% (15/25) 
1-6/section, CD45+ (no 
thyrocytes) 
GD 40% (6/15) ND 
Thyroid adenoma 22% (2/9) ND 
Klintschar et 
al. [6] 
HT Paraffin-embedded 
thyroid tissue 
Qualitative PCR SRY and 
Amelogenin 
47% (8/17) ND 
Nodular goiter 4% (1/25) ND 
Klintschar et 
al. [10] 
HT 
Paraffin-embedded 
thyroid tissue 
Qualitative PCR of DYS14 
of Y chromosome 
38% (8/21) 15-4900/100.000 
Multinodular goiter 5% (1/18) 182/100.000 
Healthy 0% (0/17) ND 
Ando et al. [9] 
GD Paraffin-embedded 
thyroid tissue 
PCR-ELISA SRY 
20% (4/20) ND 
Thyroid adenoma 0% (0/6) ND 
GD Fresh-frozen thyroid 
tissue 
85% (6/7) 14-295/100.000 
Thyroid adenoma 25% (1/4) 17/100.000 
GD 
Blood 
47% (8/17) 1-10/100.000 
Healthy 28% (4/14) 1-87/100.000 
Polycystic ovary syndrome never 
pregnant 
0% (0/16) 0/100.000 
Srivatsa et al. 
[8] 
Various thyroid disorders, without 
documented male children 
Paraffin-embedded 
thyroid tissue 
FISH 
44% (4/9) 
1-165/section, individual or 
in cluster Various thyroid disorders, with 
male children 
63% (12/20) 
Healthy controls 0% (0/8) ND 
ND: not determined 
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However, as shown by Ando et al. [9], data obtained on paraffin-embedded tissue are difficult to 
compare with data obtained on fresh-frozen material as paraffin-embedded tissue is subject to DNA-
fragmentation. Moreover, techniques used to study fetal microchimerism, Fluorescence in situ 
Hybridisation (FISH), qualitative and quantitative PCR, have different sensitivities influencing the 
results of the studies [5,9]. 
In patients without history of male full-term pregnancy, male microchimerism has been found in 
blood and in the thyroid gland [9,11]. Abortion or undetected miscarriage can however also lead to 
microchimerism as transfer of microchimeric cells starts at the fourth week of pregnancy [12]. 
Studies investigating the occurrence of unrecognized miscarriages have reported that the rate of 
pregnancy loss prior to the first missed period is approximately 22-30% [13]. Moreover, other 
sources of microchimerism, natural and iatrogenic, have been described. Not only do fetal cells cross 
the placenta and enter into the maternal circulation during pregnancy, but due to a bidirectional 
transfer between the mother and the fetus, maternal cells can also enter the fetal circulation. The 
latter has been described in tissues of patients with different diseases such as type 1 diabetes [14-16]. 
Other naturally acquired sources of microchimerism include feto-fetal transfer from an undetected 
vanishing twin [17], or possibly from an older sibling. Iatrogenic sources of microchimerism include 
blood transfusion and organ transplantation [18]. Results of studies describing fetal microchimerism 
in AITD must therefore be interpreted carefully. 
Fetal microchimeric cells in autoimmune thyroid diseases: harmful, beneficial or innocent for the 
thyroid gland? 
The consequences of long-term persistence of fetal microchimerism are difficult to assess to date. As 
fetal microchimerism in peripheral blood is an almost universal finding during normal pregnancy [19] 
and during the postpartum period [4,20], the presence of fetal cells in the circulation does not 
indicate an aberrant immune response by the mother. An actual active role of fetal cells in 
autoimmune diseases has not yet been proven, only the presence of these cells in tissues affected by 
the disease. The mechanism that attracts fetal cells to migrate into the maternal thyroid gland has 
not yet been studied. Cytokines, chemokines, and adherent factors may be involved [21]. 
There are a number of potential mechanisms by which fetal immune and non-immune cells may 
influence the autoimmune status of the mother. Harmful, beneficial as well as innocent effects have 
been assigned to the long-term persistence of fetal microchimeric cells [22]. In a harmful way, fetal 
cells can cause autoimmune thyroid disease by initiating a graft-versus-host reaction (GvHR), or the 
maternal host can initiate a host-versus-graft reaction (HvGR) against intrathyroidal fetal cells. In a 
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beneficial way, fetal cells can offer help in tissue repair. Another hypothesis suggests that fetal cells 
are innocent bystanders in the thyroid gland and do not participate in the autoimmune reaction. 
Harmful 
It is possible that fetal cells themselves play an active role in determining the maternal immune 
repertoire. Postpartum, fetal immune cells can interact with maternal cells and may initiate the onset 
of postpartum AITD [23,24]. Presence of fetal cells in the thyroid gland [6-10], where the 
autoimmune reaction is taking place, supports this hypothesis.  
Fetal cells could act as effector cells initiating a GvHR (hypothesis 1) or could be target of an HvGR 
(hypothesis 2). After delivery, when placental immune suppression is lost, fetal immune cells may 
become activated and initiate an autoimmune reaction based on HLA dissimilarities. The activation of 
fetal immature T cells, monocytes, macrophages and NK cells and the production of inflammatory 
cytokines and chemokines are believed to initiate the autoimmune disease (hypothesis 1) [25,26]. 
Alternatively, fetal cells could be recognized as partially allo-immune and give rise to an autoimmune 
reaction by a direct response of the maternal cells to the fetal cells or by molecular mimicry between 
fetal antigens and intrathyroidal maternal antigens (hypothesis 2) [27-29] . 
Hypothesis 1: Microchimerism induces a graft-versus-host reaction (GvHR) 
During pregnancy, circulating fetal cells do not initiate disease, which indicates the success of 
placental immune suppression. After pregnancy, once maternal tolerance against fetal cells is lost 
[23], fetal cells could become activated due to an unknown factor. Triggers can be viral or bacterial 
agents, drugs or abnormal tissue proteins [30]. Accumulating evidence suggests that these activated 
fetal microchimeric cells initiate a local immune GvHR. Similarities between autoimmune diseases 
and graft-versus-host disease (GvHD) suggest a functional role for fetal microchimerism to initiate a 
GvHR.  
To be able to initiate a GvHR, three conditions must be fulfilled [31]. First of all, fetal cells have to be 
present at the site of the immune reaction. As fetal cells have already been detected in  blood [4,9] 
and thyroid glands of patients with AITD [6-10], this condition is fulfilled. Secondly, the microchimeric 
cells must be immunologically competent T or B cells. In blood of patients with HT, mainly fetal CD8
+
 
cytotoxic T cells were detected [4]. In our opinion, these fetal cytotoxic T cells could cause cell death 
leading to hypothyroidism [32]. In patients with GD, the majority of fetal cells was found in the B cell 
fraction [4]. These B cells could possibly be activated by fetal CD4
+
 T cells, also detected in the blood 
of these patients. From our point of view, it can be presumed that fetal thyroid-reactive T cells could 
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cause activation of B cells, secreting TSHR-stimulating antibodies causing hyperthyroidism [32]. 
Thyroid auto-antibodies have already been described in blood [33]. These mechanisms are illustrated 
in Figure 1, upper left. 
Even fetal progenitor cells have been shown in maternal blood and tissues subject to autoimmunity 
[34-36]. It is possible that these progenitor cells develop in the maternal thymus and bone marrow 
into respectively functional T and B cells, as shown in mice [37], and migrate into the maternal 
thyroid gland where they start an immune reaction. However, some level of HLA compatibility is 
necessary to survive positive and negative selection in the thymus and periphery, which has been 
shown in systemic sclerosis (SSc) [20]. Moreover, the presence of fetal CD3
+
 T cells [26] and CD4
+
 T 
cells [38] has been proven, which leads to the hypothesis that fetal cells could start an immune 
reaction against maternal cells.  
Thirdly, microchimeric cells must recognize the cells of the host as foreign. In patients with SSc, in 
contrast to controls, CD28 stimulation of PBMCs caused an increase in the amount of fetal cells [39]. 
T cell clones have been isolated from female patients with SSc which turned out to be self-reactive 
and appeared to be male in origin. These clones produced higher concentrations of IL-4 than control 
clones did [40]. These results suggest that the fetal cells were immunologically active and able to 
proliferate, and that one of the immune targets of these fetal immune cells were maternal antigens. 
This has to be confirmed for AITD.  
An argument against this hypothesis is the low concentration of the fetal cells in the maternal 
circulation [4,6], and that only a part of all patients with AITD show microchimerism in their thyroid 
gland [6-10]. In patients who appear to be negative however, it is possible that fetal microchimeric 
cells are not detectable by the methods used, that microchimeric cells originate from another 
(natural or iatrogenic) source or that the clinical context of the studied samples is not properly 
described. It is also possible that only female fetal cells, provoking the immune reaction, are present 
[6]. Our study of microchimerism in blood of patients with AITD however, showed male fetal cells in 
all patients with an AITD. Taken together, these data suggest a potential role of fetal cells in the 
pathogenesis of AITD [4,6]. 
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Figure 1: Potential mechanisms of harmful (red), beneficial (green) and innocent (blue) microchimerism in the 
thyroid gland. 
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Hypothesis 2: Microchimerism induces a host- versus-graft reaction (HvGR) 
Alternatively, fetal cells could initiate AITD by being the target of a HvGR [27]. Fetal microchimeric 
cells have to be recognized by the mother as foreign. Because fetal cells contain paternal genes, the 
cells are semi-foreign to the mother. After delivery, once the immune tolerance mechanisms of the 
mother are no longer present, maternal cells may react against the paternal antigens of the 
intrathyroidal microchimeric cells [6,8,10]. Maternal cells could induce an immune reaction by a 
direct response to microchimeric cells or by cross-reactivity due to molecular mimicry [41], both 
illustrated in Figure 1, upper right. 
In case of a direct response to microchimeric cells, fetal cells can initiate a GvHR against maternal 
antigens upon which intrathyroidal maternal autoreactive T cells become activated which eventually 
leads to the maternal cells causing damage to the tissue. Another possibility is that fetal antigen 
presenting cells present maternal antigens to maternal immune cells resulting in an immune reaction 
from the mother against her own cells [42]. In molecular mimicry, maternal cells start an immune 
reaction against fetal antigens, but due to similarities between fetal antigens and maternal thyroidal 
self-antigens, autoimmunity to the thyroid occurs [41].  
Evidence for this HvGR hypothesis is shown in morphea or localized scleroderma, where fetal 
microchimeric cells were mainly displaying an antigen-presenting role as B cells and dendritic cells 
[43]. In addition to this study, the maternal immune system is directly responsive to fetal cells since 
the level of microchimeric cells seems dependent on the level of fetal-maternal compatibility, at least 
in animal models [44]. 
Beneficial 
An argument against a harmful role of microchimeric cells is the fact that fetal cells have also been 
detected in healthy women without signs of autoimmunity [7,8,45]. Male cells have been detected in 
thyroid, lung, lymph node and skin in women with sons and in kidney, liver and heart in women with 
and without sons [46]. In the latter group of women, an unrecognized miscarriage of a male fetus 
could have occurred. Presence of fetal microchimeric cells in affected and healthy women suggests 
that these cells do not play a direct role in triggering maternal autoimmune disorders. Instead of 
causing an autoimmune reaction, they could be a part of tissue repair. 
Hypothesis 3: Microchimeric cells repair injured tissue 
Beneficial microchimerism has mainly been described in cancer [47-49]. The first study on fetal 
microchimerism in cancer was performed by Cha et al. [47] In this study, male cells were detected in 
cervical tissue of patients with cervical cancer. However, Gadi et al. [50] were the first to make an 
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association between the presence of fetal microchimerism and the influence of pregnancy in breast 
cancer. As breast cancer was less prevalent in parous women compared to nulliparous women, fetal 
microchimeric cells may reduce the risk of developing breast cancer. Also, fetal microchimerism was 
less present in peripheral blood of women with breast cancer than in healthy women [50]. According 
to Dubernard et al. [51], fetal cells are recruited from the peripheral blood into the damaged tissue 
to repair it if malignancies are developed during pregnancy. Fetal microchimerism has also been 
investigated in thyroid cancer, cervical cancer, lung cancer and melanoma [8,47-49,52,53]. The 
proposed role of fetal microchimerism in cancer has been a beneficial one, although a role in disease 
progression has also been considered as fetal cells can contribute to lymphangiogenesis or tumor 
growth [53]. In mice, fetal progenitor cells participate in inflammation and angiogenesis during 
wound healing [54]. 
If fetal cells do have a function in tissue regeneration, two conditions must be fulfilled: they have to 
migrate to the damaged area and they have to show plasticity. During pregnancy, fetal progenitor 
cells have been detected in maternal blood and tissues [36,55]. They are capable of engrafting into 
maternal bone marrow [56]. After pregnancy, fetal microchimeric cells expressing tissue specific 
markers have been found in maternal tissues, both healthy and affected [46]. In humans, fetal 
hepatocytes [34,57,58], cardiomyocytes [59], endothelial cells, bone and cartilage [60] and intestinal 
epithelium [34] have been detected. In animal models, fetal hepatocytes [61], kidney tubular 
epithelium [61], neurons [62] and glia [63], and cardiomyocytes [64] have been detected. These data 
suggest that fetal progenitor cells are capable of differentiating into tissue specific mature cells 
within injured maternal organs [34,65]. The diversity of cell types into which microchimeric cells can 
apparently differentiate, suggests that a very early stem cell type is involved, the pregnancy-
associated progenitor cells (PAPCs) [34,66].  
In patients with multinodular goiter, fetal epithelial cells were detected. 14% to 60% of these cells 
stained positively with cytokeratin, a marker of epithelial differentiation [34]. Fetal microchimeric 
cells were also observed in thyroid glands of patients with various thyroid disorders, such as 
adenoma and thyroid carcinoma, but were absent in necropsy specimens from normal thyroid glands. 
Fetal cells were detected both individually and in clusters. In one patient with a progressively 
enlarging goiter, fully differentiated male thyroid follicles closely attached to and indistinguishable 
from the rest of the thyroid were observed [8]. In some patients with papillary thyroid cancer, fetal 
microchimeric cells were detected in tumor tissue as single cells or in clusters [48]. Presence of 
microchimeric progenitor cells in the adult thyroid gland could be a potential source for tissue 
regeneration [28,67], as shown in Figure 1, lower left. In women with papillary thyroid cancer, the 
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prevalence of male DNA was reduced in peripheral blood compared to healthy women [67]. As in 
other cancers, the specific homing to the injured tissue may explain their reduced number in 
maternal peripheral blood.  
Adapting the phenotype of the cells in the maternal tissue is however not sufficient to dedicate a role 
in tissue repair as its function has not yet been proven. Moreover, it can be hypothesized that after 
successful repair by chimeric cells, a HvGR to these microchimeric cells could still be induced at a 
later time, if an altered immunological response occurs [41]. 
Innocent 
Hypothesis 4: Microchimeric cells as ‘innocent bystanders’ 
A fourth hypothesis suggests that fetal microchimeric cells are innocent bystanders and do not 
participate in triggering or exacerbating AITD [3]. 
Reports mentioned that a certain disease activity threshold is necessary for the significant detection 
of fetal microchimeric cells, suggesting that their presence is a consequence and not a cause of the 
disease [66,68]. It is possible that the microchimeric cells are equally distributed throughout the body. 
If tissue damage occurs, fetal cells will be attracted due to inflammatory infiltrates and the level of 
microchimerism in the diseased tissue will be higher compared to that of the healthy tissue, which 
would imply that there is no relation to the pathogenesis of the disease itself [41]. The relationship 
between inflammation and the presence of microchimerism could be indicative of this theory [69]. 
Fetal intrathyroidal cells, even immune cells, could therefore be a reflection of an ongoing local 
immune reaction without active participation [70]. Due to damage to the blood vessels, fetal cells 
could leak out into the damaged tissue without having an active role in tissue damage or repair [12]. 
This has been shown in Figure 1, lower right. Because pregnancy is very common and autoimmune 
diseases are quite rare, it is likely that only certain subsets of microchimeric cells have pathogenic 
potential, while most of them are only innocent bystanders. 
An argument in favor of this hypothesis is the fact that three large epidemiological community-based 
studies failed to demonstrate an association between pregnancy, parity, abortion, and the presence 
of thyroid autoantibodies or thyroid dysfunction [71-73]. Fetal cells would only be a remnant of 
pregnancy. In contrast, a case-control study indicated parity as a potential risk for AITD by showing 
higher thyroid autoantibody levels in women with previous pregnancies compared to non-parous 
women [74]. However, HLA compatibility between fetal and maternal cells might be a more crucial 
risk factor than the number of pregnancies in the initiation of the autoimmune reaction by fetal 
microchimeric cells [7]. 
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Conclusion 
Microchimerism might have harmful, beneficial or innocent effects for the mother depending on a 
number of factors including the origin of the microchimeric cells, type of cells acquired, tissue 
environment, type of malignancy, time elapsed since microchimerism acquisition and age of the 
recipient. HLA haplotype and degree of differences between mother and child have the potential to 
affect the balance of beneficial versus harmful consequences of microchimerism for the recipient 
[75]. In our opinion, the more fetal cells show similarities with the maternal cells, the more likely 
they have the potential to start a GvHR once they have been activated by yet undetermined 
mechanisms. 
Whether the higher prevalence of microchimerism in thyroid autoimmunity is mere coincidence or is 
a marker for immune-mediated disease requires further investigation. Further research to 
characterize the fetal cells detected in blood and tissues is mandatory.  
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The Laboratory of Pharmaceutical Biotechnology, which is part of the Forensic Institute of Ghent 
University,  performs forensic DNA analyses, mainly for the Belgian magistracy. Besides forensic DNA 
analyses, procedures to analyze forensic samples are continuously optimized and improved.   
One of the first steps in the analysis of forensic evidence is the search for biological material, such as 
blood, sperm, saliva and hairs, that can subsequently be used for DNA profiling. In this part of the 
thesis, the aim was to optimize and validate a fast screening method to select hairs useful for DNA 
analysis and to optimize a method to visualize bloodstains on dark fabrics. 
Human hairs are frequently recovered as forensic evidence as humans shed about 150 hairs daily 
[1,2]. The identification and comparison of human and animal hairs can be helpful in demonstrating 
physical contact with a suspect, victim, and crime scene. Formerly, the use of a microscope was 
considered to be the only reliable tool for the identification and microscopic comparison of the hair 
recovered from the crime scene. Today, nuclear and mitochondrial DNA analysis can provide 
additional information. The success rate of nuclear DNA analysis of hair roots found at a crime scene 
is however quite low and negative results of hair analysis are frequently reported [3,4]. The aim of 
this study was to develop a fast nuclear staining method to predict the success rate of DNA analysis 
of hairs in forensics (Chapter 2).  
Blood is a common body fluid often detected on pieces of evidence found at crime scenes, especially 
at scenes of violent crimes. Before DNA profiling can be performed, the presence of a bloodstain 
needs to be made visible. Especially when blood is present on a dark background, e.g. a dark fabric, 
the stain might be invisible for the naked eye. Therefore, the use of a visualization assay was 
optimized and validated to be able to detect bloodstains on different fabrics. Moreover, the 
combination of this assay with several presumptive blood tests was evaluated (Chapter 3). 
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Abstract 
Human hairs are frequently recovered as forensic evidence as humans shed about 150 hairs daily. 
The success rate of STR profiling of these hair roots is however quite low and negative results of hair 
analysis are frequently reported. To increase the success rate of DNA analysis of hairs in forensics, 
nuclei in hair roots can be counted after staining the hair root with DAPI, a fluorescent and non-
destructive nuclear stain. Two staining methods were tested in order to reduce the incubation time 
with DAPI: a longer method with two 1 hour incubations in respectively a DAPI- and a wash-solution, 
and a fast, direct staining of the hair root on microscope slides. 
The two staining methods were not significantly different. The results of the STR analysis for both 
procedures showed that 20 nuclei are necessary to obtain at least partial STR profiles. When more 
than 50 nuclei were counted, full STR profiles were always obtained. In 96% of the cases where no 
nuclei were detected, no STR profile could be obtained as expected. However, 4% of the DAPI-
negative hair roots resulted in at least partial STR profiles. Therefore, each forensic case has to be 
evaluated separately in function of the importance of the evidential value of the found hair. The fast 
staining method was applied in 36 forensic cases on 279 hairs in total.  
To our opinion, this fast staining method of hair roots with DAPI can be used to increase the success 
rate of hair analysis in forensics. Hair roots containing any visible nuclei will be selected for STR 
analysis. 
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Introduction 
The identification of biological samples collected at crime scenes is established by DNA typing of 
different Short Tandem Repeat (STR) loci. As humans shed about 150 hairs daily, hairs from the 
victim or from the putative offender are frequently found at crime scenes [1,2].  Microscopic analysis 
of the hair can identify the origin of the hair (human or animal), establish the nature or shape of the 
hair tip, pigment pattern and color, and determine whether the hair has a root or not [3]. However, 
microscopic comparison between hairs collected at a crime scene and reference hair is very labor 
intensive and in most cases, no reference hair is available for comparison. Moreover, collection of 
hairs from a suspect might take place many months, possibly years, after the crime. Hence, the 
characteristics of the reference hair sample may look quite different from the hairs shed at time of 
the crime. The discriminative power of microscopic analysis is thus relatively small.  
In contrast, STR analysis of the hair root can identify the donor of the hair. In many forensic cases 
however, no reportable STR profiles are obtained from hairs collected at crime scenes [4,5]. This can 
be explained by the growth phase of the hair. Hairs with intact root in the mitotically active anagen 
growing phase consistently yield reportable STR profiles while the inactive, naturally shed hairs in the 
telogen phase rarely yield informative STR profiles [5-9]. Unfortunately, 95% of the hairs found at a 
crime scene are telogen hairs [8,9].  
The aim of this study was to optimize and validate a fast, non-destructive, easy to perform and 
inexpensive screening method to select those hair roots useful for STR analysis. Nuclear DNA can be 
stained with haematoxylin [3], which is known to reduce DNA yield [10,11], or can be labeled in situ 
[12] which is very time-consuming. Nuclei in hair roots can also be stained overnight with 4’,6-
diamidino-2-phenylindole or DAPI, a fluorescent dye that binds strongly to A-T rich regions in DNA 
[8,13]. The aim of this study was to validate a shorter staining protocol with DAPI, based on the 
protocol described by Bourguignon et al. [8], and to evaluate the impact of the staining on 
subsequent STR profiling. Furthermore, the influence of forensic adhesive films, used to collect hairs 
at a crime scene, was investigated. 
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Materials and methods 
Staining of hair roots with 1 hour incubation in DAPI (part I) 
58 hairs (plucked or spontaneously shed hairs) were collected from 9 volunteers. Hair roots were 
isolated by cutting the hairs approximately 1 cm above the hair root and were individually put into 
sterile 1.5 ml microcentrifuge eppendorfs. 10 µl of a DAPI/DABCO-solution (1.6 mg DAPI (Sigma); 
2.24 g DABCO (1,4-diazabicyclo (2,2,2) octane) (Sigma), 10 ml Tris-HCl 0.2 M; pH 7.4) and 90 µl 
glycerol (Sigma) was added to the hair root. After 1 hour incubation at room temperature in the dark, 
the hair root was removed from this solution and transferred to another microcentrifuge eppendorf. 
10 µl of a wash-solution (2.24 g DABCO; 10 ml Tris-HCl 0.2 M pH 7.4) and 90 µl glycerol was 
subsequently added to the hair root. After 1 hour incubation, hair roots were removed from this 
wash-solution and put on UV-sterilized microscope slides cleaned with bleach and 70% ethanol. 10 µl 
of the wash-solution was added to the hair root and a coverslip glass was applied.  
DAPI-staining of hair roots directly on microscope slides (part II) 
As a preliminary test to evaluate whether the staining procedure could be shortened even further by 
performing the DAPI-staining directly on hair roots on microscope slides, 23 hairs (plucked or 
spontaneously shed hairs) were collected from 7 volunteers. Hair roots were isolated as described 
above and were put on microscope slides, upon which 20 µl DAPI/DABCO-solution was added to the 
hair root. A coverslip glass was applied and hair roots were immediately visualized under the 
fluorescence microscope. 
To compare both staining methods, hair roots of 54 naturally shed hairs from 5 donors were stained 
directly on microscope slides (part II) upon which images were acquired. In a next step, hair roots 
were removed from the microscope slide and were stained again using the method described in part 
I. Images were again acquired. Both images of the same hair root were compared to each other.  
Hairs on adhesive films 
To investigate the influence of possible loss of nuclei due to the adhesive tape, 10 hairs plucked from 
1 donor were collected using adhesive films from the tape lifting kit (distributed by National 
Institution for Criminalistics and Criminology, Belgium). These hairs were removed from the adhesive 
film and were stained directly with DAPI on microscope slides as described in part II of the staining. 
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Forensic cases 
The screening method described in part II was applied on 279 hairs, collected in 36 forensic cases. 
Hairs were mainly collected from clothes and some from tape lifting kits applied on car seats. 
Microscopic evaluation of the staining 
Image acquisition was carried out with an AxioVert 200M inverted fluorescence microscope (Carl 
Zeiss), equipped with the AxioVision multichannel fluorescence module and an AxioCam MRm 
camera (Carl Zeiss). Cell nuclei were visualized using Zeiss filter set no. 49 (G 365 nm, FT 395, BP 
445/50). Slides were screened at 10x or 20x magnification using a Carl Zeiss short distance Plan-
Apochromat® objective [14]. Hair roots were examined across several focal planes in order to 
confirm whether nuclei were present. DAPI fluorescent blue spots showing the shape and size of the 
human follicular cells (~3 – 6 µm) were counted according to Bourguignon et al. [8]. 
DNA extraction 
After microscopic evaluation, hair roots were removed from the microscope slide and transferred in 
a 1.5 ml microcentrifuge tube. 200 µl 5% Chelex®100 (Bio-Rad) was added to the hair root [15]. After 
vortexing for 10 s, samples were incubated overnight at 56°C in a Thermomixer (Eppendorf). The 
following day, samples were incubated at 100°C for 8 minutes. Finally, samples were centrifuged for 
3 min at 14000 x g [16]. 
DNA amplification and detection 
All samples were amplified using an in house developed multiplex of 14 short tandem repeat (STR) 
loci (D3S1358, TH01, D21S11, D18S51, vWA, D8S1179, TPOX, FGA, D5S818, D13S17, SE33, CD-4, 
D7S820 and D16S539) and amelogenin [16,17]. Amplified fragments were separated and analyzed by 
capillary electrophoresis using an ABI PRISM 3100 or 3500xL Genetic Analyzer equipped with 
Genemapper ID-X 1.2 software (Life Technologies). Peak height minimum thresholds were set at 100 
relative fluorescence units (RFU). Each STR profile of an analyzed hair root was compared to the STR 
profile of the donor of the hair. Profiles were subdivided into full (all loci gave interpretable results), 
partial (result for one or more loci did not meet the minimum thresholds) or no profile.  
Statistical analysis 
Level of significance was calculated by SPSS (IBM, New York, US) using the McNemar test. A p-value 
<0.05 was regarded as significant.  
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Results and discussion 
1 hour incubation in DAPI (part I) 
58 hair roots stained with DAPI for 1 hour, were subdivided into 4 groups depending on the number 
of visible nuclei as shown in Table 1. An example of a hair root without visible nuclei is shown in 
Figure 1A while an example of a hair root with more than 50 nuclei is shown in Figure 1B.  
Results of STR profiling of these 58 hair roots are shown in Table 1. If 20 or more nuclei were 
observed, at least partial profiles could be obtained. STR profiling of hair roots containing more than 
50 nuclei resulted in full STR profiles. All 38 hair roots without any visible nuclei resulted in no STR 
profile.  
Table 1: STR profiling of 58 hair roots stained with DAPI for 1 hour 
Number of visible 
nuclei 
Total root N N roots with STR profile 
Full profile Partial profile No 
0 38 0 0 38 
<20 4 2 0 2 
20<n<50 4 3 1 0 
>50 12 12 0 0 
 
Direct staining of hair roots with DAPI on microscope slides (part II) 
To investigate whether direct staining with DAPI could also be used to screen hair roots suitable for 
STR analysis, 23 hair roots were stained directly on microscope slides and images were acquired 
immediately afterwards. An example of a hair root without visible nuclei after direct DAPI-staining on 
microscope slides is shown in Figure 1C; Figure 1D shows a hair root with more than 50 nuclei.  
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Figure 1:  Hair root without visible nuclei (A) and with more than 50 nuclei (B)  
stained with DAPI for 1 hour (part I). Hair root without visible nuclei (C)  
and with more than 50 nuclei (D) stained directly on microscope slides (part II). 
Results of the STR analysis of these 23 hair roots are shown in Table 2. The results of this preliminary 
test were comparable with those obtained after staining with one hour incubation. Even more, in all 
cases where nuclei were observed, full STR profiles could be obtained. All hair roots without visible 
nuclei resulted in no STR profile. 
Table 2: STR profiling of 23 hair roots stained directly on microscope slides 
Number of visible 
nuclei 
Total root N N roots with STR profile 
Full profile Partial profile No 
0 11 0 0 11 
<20 1 1 0 0 
20<n<50 5 5 0 0 
>50 6 6 0 0 
 
To be sure whether the immediate staining on the microscope slides would lead to the detection of 
the same number of nuclei compared to the staining with one hour incubation, the two staining 
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methods were performed on the same hair roots and compared. As nuclei of plucked hairs are 
immediately visible after direct staining of the hair root on microscope slides, focus has been put on 
naturally shed hairs, mimicking forensic situations. 54 hair roots of naturally shed hairs were first 
directly stained on microscope slides according to the protocol described in part II. After image 
acquisition, the same hair roots were stained again according to the protocol described in part I in 
which hair roots were incubated with DAPI for 1 hour and wash-solution for 1 hour. There were no 
significant differences between the two staining methods (McNemar test, p = 1.00), except for one 
hair. In this exception, direct staining of the hair root on a microscope slide resulted in detection of 
less than 20 nuclei, while staining with one hour incubation in DAPI resulted in detection of more 
than 50 nuclei. Evaluation of the staining and results of the STR analysis of these 54 hairs are shown 
in Table 3.  
Table 3: Evaluation of the staining and STR analysis of 54 hair roots  
Number of visible 
nuclei 
Total root N 
after direct 
staining 
Total root N 
after staining 
with 1h 
incubation 
N roots with STR profile 
Full 
profile 
Partial 
profile 
No 
0 49 49 1 3 45 
<20 5 4 4 (3
a
) 0 1 
>50 0 1 0 (1
a
) 0 0 
a
 number of roots with STR profile after staining with 1h incubation 
Counting less than 20 nuclei, all hair roots but one resulted in full STR profiles. From the 49 hair roots 
without any visible nuclei, 3 resulted in a partial STR profile and 1 even in a full STR profile. 1 of the 
hair roots which resulted in a partial profile, showed presence of adhering material, presumably 
dandruff. Adhering material however, can contain DNA and could therefore result in a STR profile. 
In an optimal situation, hair roots without visible nuclei could be discarded. In 96% (94/98) of all 
cases where no nuclei were observed, no STR profile was obtained. However, in 4% of these cases, a 
full or partial STR profile could be obtained. Therefore, results of DAPI-staining should always be 
considered in function of the importance of the evidential value of the found hair. If the hair is the 
only biological evidence in the forensic case, one might consider to submit the hair to STR analysis 
anyway, even if the staining is considered to be negative. If necessary, multiple hair roots can be 
pooled for STR analysis. In case the hair root did not yield a STR profile, the remainder of the hair can 
still be submitted to mitochondrial DNA analysis [18,19]. However, as STR analysis has a higher 
discriminative power compared to mitochondrial DNA analysis, the former is preferred. 
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Hairs on adhesive films 
Ten hairs plucked from 1 donor were collected using the tape lifting kit, subsequently removed from 
the adhesive film and directly stained on microscope slides. In 8 of 10 cases, 21 to 50 nuclei were 
counted while in the remaining 2 cases, more than 50 nuclei were observed. In all cases, full STR 
profiles were obtained (data not shown). However, loss of nuclei after removing the hair root from 
the adhesive film could be observed as the adhesive film was re-examined under the fluorescence 
microscope and nuclei were found on the tape. 
Therefore, if adhesive films are used for collecting hairs from a crime scene, it can be interesting for 
STR analysis to include that part of the tape where the hair root was located.   
Success rate experimental data 
In the experimental data presented above, 47 of 145 hair roots showed visible nuclei after DAPI 
staining. 44 of them resulted in a full or partial STR profile, which means that a success rate of 94% 
could be obtained. Assuming all these hairs would have been found at a crime scene and no 
screening method would have been applied, all 145 hairs would have been submitted to STR analysis 
and a success rate of only 30% (44/145) would have been obtained. This shows the effectiveness of 
this fast screening method using DAPI to select hairs suitable for successful STR analysis.   
Forensic cases 
The presented fast screening method was applied in 36 forensic cases in which 279 hair roots were 
stained with DAPI directly on microscope slides (part II). 263 hair roots were quoted negative. 
Although hair roots without visible nuclei were not selected for STR analysis, 8 of these hair roots 
were submitted to STR analysis anyway because adherent material was present around the hair root. 
However, no STR profile could be obtained on these hair roots. All hair roots containing any nuclei (n 
= 16), were submitted to STR analysis. Results are shown in Table 4.  
 
Table 4: STR profiling of hair roots stained with DAPI directly on microscope slides in forensic cases 
Number of visible 
nuclei 
Total root N N roots with STR profile 
Full profile Partial profile  No
 
<20 6 1 2 3 
20<n<50 4 2 2  0 
>50 6 6 0 0 
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Similar to the experimental data, full STR profiles could be obtained on the 6 hair roots with more 
than 50 visible nuclei. Two hair roots containing 20 to 50 nuclei, (one of them collected from an 
adhesive film), resulted in a full STR profile, while the other 2 resulted in a partial STR profile. As 
mentioned earlier, minimum 20 nuclei are required to obtain at least partial STR profiles. From the 6 
hair roots with less than 20 visible nuclei, 1 resulted in a full STR profile, 2 in a partial STR profile and 
the other 3 in no profile.  
Using the proposed fast screening method, all hair roots containing any nuclei should be submitted 
to STR analysis. However, one needs to keep in mind that the success rate of STR analysis of hair 
roots collected from a crime scene could be lower than the observed experimental success rate as 
adverse environmental condition prior to collection could influence the results. 
 
 
 
  
CHAPTER 2 
 
 
126 
Conclusion 
In conclusion, a fast screening method using DAPI to stain nuclear DNA in hair roots collected at a 
crime scene can be used to predict STR analysis success. This non-destructive, quick and inexpensive 
screening method which does not require an incubation time, allows the forensic DNA laboratory to 
analyze only the most promising hair roots, containing any nuclei. Therefore, judiciary costs can be 
reduced. DAPI-negative hair roots can result in a STR profile in 4% of the cases, which means that 
each forensic case has to be evaluated in function of the importance of the evidential value of the 
found hair.  
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Abstract 
In forensics, bloodstains on dark fabrics might be invisible for the naked eye. Although several 
visualization, presumptive and confirmatory blood tests have been developed, all have one or more 
disadvantages, especially on DNA analysis. 
We report the use of a visualization assay that can visually detect blood drops up to 1/20 dilution. In 
this assay, the fabric is placed between 2 wet filter papers and covered by glass surfaces on both 
sides. Pressure is applied on the glass surfaces in which bloodstains transfer onto the filter papers 
through capillary forces. Detected stains can be tested with other more sensitive presumptive blood 
performed on the filter paper. Even more, DNA analysis can be performed on the transferred 
bloodstains. 
This presented visualization is easy to perform, extremely cheap, requires little hands on time and 
does not affect bloodstain pattern analysis.  
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Introduction 
One of the first steps in the analysis of forensic evidence is the search for biological material that can 
subsequently be used for DNA extraction and profiling. Many types of body fluids on forensic 
evidence, originating from suspect or victim, can be used for DNA profiling, such as blood, semen, 
saliva, vaginal fluid, urine and sweat [1]. Blood is a common body fluid detected on pieces of 
evidence found at crime scenes, especially at scenes of violent crimes. Before DNA profiling can be 
performed, the presence of a potential biological stain, e.g. blood, needs to be visually detected. 
White light and the visible eye or a low power microscope can be used for a standard examination of 
an item of clothing. However, when blood is present on a dark background, e.g. a dark fabric, it might 
be invisible for the naked eye.  
Several visualization, presumptive and confirmatory blood tests have been developed and evaluated 
[2-8]. The potential presence of blood on a dark background can be visualized by an alternate light 
source such as Polilight [9,10]. Blood does not show significant autofluorescence but has its 
absorption maximum at 415 nm. As an alternative, infrared (IR) illumination can be used [8] in which 
an additional light source emitting wavelengths between 800 and 1000 nm, an IR-sensitive camera 
and image capture software package are necessary to visualize bloodstains. However, this is not 
standard equipment present in a forensic DNA lab. 
Other blood tests can basically be divided into two groups: presumptive blood tests based on the 
peroxidase activity of hemoglobin (Hb), the oxygen-transport metalloprotein present in red blood 
cells, and confirmatory blood tests based on immunological testing. 
One of the oldest visualization/presumptive tests for blood is the luminol test [4]. Luminol exhibits 
chemiluminescence when oxidized by Hb [11], is specific for blood and insensitive for other biological 
fluids. Luminol can, for example, be used to detect latent bloodstains on large surfaces such as a 
concrete floor at a crime scene where the offender tried to efface blood by thorough cleaning. 
However, luminol cannot be used for the detection of bloodstains on dark fabrics as DNA 
degradation can occur [7,12]. Moreover, luminol needs to be applied in a dark room. Similarly, the 
fluorescein test is based upon oxidation of fluorescin to fluorescein in the presence of Hb and 
hydrogen peroxide [3,5,6]. Fluorescein fluoresces when exposed to light at 425 - 485 nm (blue light). 
The necessity of a specific light source and working in the dark can be quite impractical when 
analyzing forensic evidence [1]. 
Chemical catalytic presumptive blood tests described are benzidine, tetramethylbenzidine, 
leucomalachite green and ortho-toludine which show different sensitivities [2,13-15]. Benzidine and 
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ortho-toludine are potent carcinogens [14,16]. Another presumptive blood test based on the 
peroxidase activity of Hb, is the Kastle-Meyer test [17,18]. However, these tests are not visualization 
tests. They only indicate if a visible stain on a fabric is blood or not.   
Non-catalytic confirmatory blood tests, e.g. Hexagon OBTI, HemeSelect and ABAcard HemaTrace, are 
based upon the reaction of antigens of human Hb with anti-human Hb antibodies labeled with a dye 
and are used to confirm if the blood is human or not. However, primate blood from different species 
may react with these tests [1,19]. As with the chemical catalytic presumptive tests, they can not be 
used for the visual detection of bloodstains on dark backgrounds. 
In this study, we report the use and validation of a visualization assay for detection of blood, 
especially on (dark) fabrics. It is based on the transfer of blood, through capillary forces, onto a filter 
paper in order to locate blood on the fabric. Detection limit and compatibility with other 
presumptive blood tests were evaluated, as well as the influence of fabric types (natural, synthetic or 
a combination of both) and weaving pattern on blood detection. 
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Materials and methods 
Samples 
Blood samples from a healthy volunteer were collected by venous puncture in EDTA sample tubes. 
In a first experiment, the visualization assay was performed on undiluted bloodstains of 20 µl, 10 µl, 
5 µl and 1 µl applied on a white and on a dark fabric in order to evaluate the usability of the 
presented visualization assay for dark fabrics. 
Subsequently, the detection limit of the visualization assay was determined. 10, 2, 1 and 0.5 µl of 
undiluted blood and 20 µl of 1/2, 1/5, 1/10, 1/20, 1/50, 1/100 and 1/500 diluted blood was added in 
duplicate on a 100% firmly woven white cotton (i.e. fabric used for T-shirts). Moreover, the 
visualisation test was evaluated in combination with a presumptive blood test (Kastle-Meyer test 
[17,18], LumiScene [7] and fluorescein test [3,6]). After the visualization assay was performed, fabrics 
and filter papers were dried in a fume hood upon which the presumptive blood tests were performed 
on both the blood spot on the fabric and the transferred blood spot on the filter paper. All tests were 
performed in duplicate at room temperature. The influence of all these tests on DNA profiling was 
determined. 
The visualization assay was repeated on 11 different types of stained and unstained fabrics (both 
natural and synthetic). All experiments were performed in duplicate at room temperature. 
Visualization assay 
Two filter papers (VWR International, Radnor, USA) were sprayed with sterile water until the filter 
was entirely wet. One filter was placed on a clean glass surface. Subsequently the fabric was placed 
on this filter and covered by the second filter and another clean glass plate. Pressure was applied by 
placing ~10 kg of weights on top of the second glass plate. During 2 hours, the filter papers were 
evaluated through the glass every 10 minutes. If red spots were observed on the filter paper, the 
visualization assay was considered to be positive and indicated the presence of blood. When no spots 
on the filter paper were observed, the test was considered to be negative.  
Kastle-Meyer test 
Kastle-Meyer (KM) reagent [17,18] was prepared by dissolving 0.2 g phenolphthalein powder (VWR 
International) in 10 ml of a 20% sodium hydroxide solution with 2 g mossy zinc (VWR international). 
After boiling the solution under reflux, 3 ml of the KM reagent was added to 10 ml distilled water and 
2 ml 70% ethanol (VWR international). The KM test was performed as described earlier [20]. A piece 
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of sterile filter paper (Sigma Aldrich, St. Louis, MO, USA) was rubbed gently on a small area of the 
stain on the fabric. A drop of 70% ethanol was added to the filter paper followed by 1 drop KM 
solution. Subsequently, a drop of 3% hydrogen peroxide (Sigma Aldrich) was added. An immediate 
pink color was indicative of blood. Alternatively, the KM test was also performed on the transferred 
bloodstains on the filter paper of the visualization assay. 
LumiScene test 
The LumiScene working solution was prepared by adding 5 ml of LumiScene stock solution 
(LumiScene Field Kit, Loci Forensics B.V., Le Nieuw-Vennep, The Netherlands) to 245 ml Milli-Q water. 
One activation tablet was added to this solution. After 5 and 10 minutes respectively, this solution 
was stirred for one minute. The working solution was loaded in the reservoir of a spray system with 
compressor (HLO 215/25, Fribel NV, Kontich, Belgium). The solution was sprayed on the fabrics or on 
the filter papers of the visualization assay for 3 seconds. The stains emitted light at 525 nm, which is 
visible for the naked eye [7].  
Fluorescein test 
The fluorescein stock solution was prepared by mixing 1.6 g NaOH (Merck, Darmstadt, Germany), 2 g 
zinc powder (Panreac, Barcelona, Spain), and 0.16 g fluorescein (C20H12O5, Sigma-Aldrich) with 20 ml 
of distilled water. After vigorous shaking, the solution was left for one hour to let the zinc powder 
settle. Meanwhile, 99 ml of oxidant was prepared by mixing 5 ml H2O2 (Merck, Darmstadt, Germany) 
with 94 ml of distilled water. The fluorescein working solution was prepared by adding 1 ml of the 
stock solution to the oxidant, carefully avoiding the addition of zinc powder. The working solution 
was then loaded into an Ecospray system (Carl Roth, Lauterbourg, France). The solution was sprayed 
on the fabrics or on the filter papers of the visualization assay for 3 seconds, while the stains were 
exposed to light of a portable xenon-lamp with a filter for emission at 450 nm (Crime Scene lamp SL-
450, Heerbrugg, Switserland). The stains emitted light in the 500-590 nm range, which could be 
viewed using yellow forensic goggles [3,6].   
DNA extraction 
DNA was extracted from all bloodstains applied on the 100% white cotton fabrics and from the 
transferred bloodstains on the filter paper using a slightly modified Chelex
®
 extraction method as 
described earlier [21]. In a first step, bloodstains were cut from the fabric and from the filter paper 
with a sterile scalpel. These stains were incubated in 1 ml sterile water for 30 minutes at room 
temperature. After incubation, the fabrics/filter papers were removed and samples were centrifuged 
at 14000 rpm for 5 minutes. Subsequently, supernatant was removed and the pellet was 
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resuspended in 200µl 5% Chelex
®
 solution (Chelex
®
100 resin, Bio-Rad, Hercules, CA, USA). After 
incubation at 56°C for 30 minutes, the samples were put in boiling water for 8 minutes. After 
centrifugation at 14000 rpm for 3 minutes, 30 µl of the supernatant was used for PCR.  
DNA amplification and capillary electrophoresis 
All samples were amplified using an in house developed multiplex of 14 short tandem repeat (STR) 
loci (D3S1358, TH01, D21S11, D18S51, vWA, D8S1179, TPOX, FGA, D5S818, D13S17, SE33, CD-4, 
D7S820 and D16S539) and the amelogenin locus [21]. Primers were purchased from Eurofins MWG 
Operon (Ebersberg, Germany) or Life Technologies (Carlsbad, CA, United States of America). Each 
reaction mix, with an end volume of 50 µl, contained 16.55 µM primer mix, 1x PCR buffer (Qiagen, 
Venlo, The Netherlands), 0.5 mM MgCl2 (Qiagen), 200 µM dNTP (Applied Biosystems), 0.4 µg/µl 
albumin (Sigma Aldrich), 5 U Hotstar Taq polymerase (Qiagen) and 30 µl DNA extract. The samples 
were amplified on an Applied Biosystems GeneAmp 9700 60-well thermal cycler. Amplification 
parameters were: preincubation at 95°C for 15 minutes, followed by 34 cycles of denaturation for 60 
seconds at 94°C, annealing for 60 seconds at 59°C and extension for 80 seconds at 72°C. This was 
followed by a final elongation step of 25 minutes at 72°C. At the end of the PCR reaction, the 
temperature was kept at 4°C. After PCR, amplified fragments were separated and analyzed by 
capillary electrophoresis using an ABI PRISM
®
 3500xL Genetic Analyzer equipped with Genemapper 
ID-X 1.2 software (Applied Biosystems). Peak height minimum thresholds were set at 100 relative 
fluorescence units (RFU). Each DNA profile of an analyzed blood spot was compared to the DNA 
profile of the donor of the bloodstain.  
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Results and discussion 
Detection limit of the visualization assay 
The presented visualization test is especially meant for the visualization of bloodstains on dark 
fabrics. Therefore, undiluted bloodstains of 20 µl, 10 µl, 5 µl and 1 µl were applied on a white (Figure 
1A) and on a dark fabric (Figure 1C). Bloodstains on the dark fabric were invisible for the naked eye. 
After 30 minutes incubation, bloodstains on both fabrics were made visible on the filter paper of the 
visualization assay (Figure 1B and 1D respectively). 
 
Figure 1: Undiluted blood stains of 20µl, 10µl, 5 µl and 1 µl on a white fabric (A) and on a dark fabric (C), 
visualized by the visualization assay (B and D respectively). Bloodstain pattern (A) remains unaffected with the 
visualization assay (B). 
Subsequently, the detection limit of the visualization assay was determined by applying 10, 2, 1 and 
0.5 µl of undiluted blood and 20 µl of 1/2, 1/5, 1/10, 1/20, 1/50, 1/100 and 1/500 diluted blood on a 
100% firmly woven white cotton. The visualization assay was positive for the undiluted blood spots 
and blood spots diluted up to 1/20. As most bloodstains on forensic evidence are undiluted and in 
many cases only present in very small amounts, the assay can easily be used to visualize bloodstains 
on dark fabrics, e.g. clothes recovered from a crime scene. 
Visualization and interpretation of latent bloodstains is an essential part of bloodstain pattern 
analysis (BPA), which is an important part of the investigation and crime scene reconstruction [22]. 
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The bloodstain pattern remains unaffected with the presented visualization assay, which is clearly 
shown in Figure 1A and 1B. Therefore, the visualization assay can be used to perform a BPA on a dark 
fabric by evaluating the transferred bloodstains on the filter paper (Figure 1D).   
Combination of the visualization assay with other presumptive blood tests and subsequent DNA 
profiling 
In a first experiment, the visualization assay was performed on a bloodstain on the fabric followed by 
a presumptive blood test on the same blood spot on the fabric. Although blood spots diluted more 
than 1/20 did not always test positive with the visualization assay, all visible blood spots on the 
fabric, diluted up to 1/500, tested positive for the presumptive blood tests, even if the visualization 
assay was performed earlier on the same spot on the fabric. Secondly, a presumptive blood test was 
also performed on the dried transferred blood spot on the filter paper. These blood spots on the 
filter paper tested positive for the presumptive blood tests. Even more, bloodstains hardly visible on 
the white fabric and not visually detected on the filter paper (blood diluted 1/500), tested positive 
with the KM test which was performed on the filter paper. In real forensic cases however, the KM 
test cannot be performed on invisible stains on the filter paper. Hence, we recommend spraying, for 
example, LumiScene on the filter paper in order to relocate bloodstains on the piece of evidence to 
be analysed. The advantage of this technique is that no DNA degradation of the stain on the fabric 
will occur. 
Regardless of the fact that the applied stain on the fabric was positive by the visualization assay, the 
stain on the fabric was subjected to DNA extraction and DNA profiling. All stains on the fabric 
generated a full DNA profile. Transferred bloodstains on the filter paper of undiluted blood spots and 
blood spots diluted 1/2, 1/5, 1/10 and 1/20, were submitted to DNA analysis. Full DNA profiles could 
be obtained on the filter paper of the undiluted bloodstains and bloodstains diluted 1/2. Therefore, 
there is no need to cut the bloodstain from the piece of fabric to obtain a DNA profile, as the 
transferred bloodstain on the filter paper can be used for DNA profiling. If no (full) DNA profile can be 
obtained from the filter paper, the stain itself should be submitted to DNA analysis. 
Our data show that the visualization assay can be combined with a presumptive blood test without 
influencing the potential of obtaining a DNA profile from the bloodstain. The visualization assay has 
to be performed first since it is a simple, easy to perform and, most importantly, inexpensive 
technique to visualize latent bloodstains on dark fabrics. If a positive result with the visualization 
assay is obtained, it should be confirmed by a presumptive blood test applied on the filter paper 
prior to DNA profiling. A confirmatory blood test, e.g. Hexagon OBTI test, could be performed on the 
bloodstain to confirm if the blood is human or not [19]. If the visualization assay is negative, this 
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means that either no blood is present on the fabric or that the blood is diluted more than what is 
visually detectable with the visualization assay. However, the most important bloodstains on the 
fabric useful for DNA analysis, will be made visible with the presented assay. In case the visualization 
assay is negative, one might consider to perform a more sensitive and more expensive presumptive 
blood test, for example LumiScene, on the filter paper or on the fabric. Detection of blood which is 
diluted more than 1/500 is interesting for forensic scientists to prove the presence of latent blood. 
This is especially the case when the offender tried to efface a bloodstain by thorough cleaning. 
However, it is less relevant for human identification by DNA profiling as these stains will theoretically 
not lead to useful DNA profiles. 
Influence of the type of fabric  
To investigate whether the type of fabric has an influence on the sensitivity of the visualization assay, 
bloodstains and blood dilutions were applied on 11 different stained and unstained fabrics of natural 
and (semi-)synthetic origin. Results are shown in Table 1. Undiluted blood drops of 10 µl and 2 µl on 
all fabric types were visually detected on the filter paper. In most cases, the visualization assay was 
positive for smaller drops of undiluted blood. 95.5% of 1 µl and 86.4% of 0.5 µl blood drops were 
visually detected on the filter paper. No clear trends were observed between different types of 
fabrics for undiluted blood.  
The type of fabric (synthetic, natural or a combination of both) on which the (diluted) blood is 
present, has some influence on the potential to visualize it with the presented visualization assay. 
With the visualization assay, 20 µl of 1/2 diluted blood was visually detected on all fabrics, while 
1/500 diluted blood was not visually detected on the filter paper on any of the fabrics. Blood 
dilutions in between those two extremes were visually detected on the filter paper as follows: 1/5: 
90.9%; 1/10: 72.7%; 1/20: 59.1%; 1/50: 22.7% and 1/100: 13.6%. Comparison of blood detection on 
natural fabrics and (semi-)synthetic fabrics showed slightly better results for natural fabrics. The 1/20 
dilution, for example, was visually detected on the filter paper on 83.3% of the natural fabrics, 
visually undetectable on the synthetic fabrics and only visually detectable on 50.0% of the semi-
synthetic fabrics. Some difference between loosely and firmly woven fabrics was observed. On 
loosely woven fabrics, somewhat more positive results with the visualization assay could be obtained 
compared to (very) firmly woven fabrics. 1/20 diluted blood was visually detected on the filter paper 
on all loosely woven fabrics in contrast to 35.7% of the (very) firmly woven fabrics. Moreover, 1/50 
and 1/100 diluted blood were visually detected with the assay on 85.3% and 50.0% of the loosely 
woven fabrics, while this was impossible on the (very) firmly woven fabrics. However, on very firmly 
woven fabrics, a more sensitive presumptive blood test can be performed. 
  
Table 1: Evaluation of the visualization assay on 11 different types of fabrics, stained or unstained, each test performed in duplicate. 
Fabric  1 2 3 4 5 6 7 8 9 10 11 
Type Natural Natural Natural Natural Natural Natural Synthetic Synthetic Semi-
synthetic 
Semi-
synthetic 
Semi-
synthetic 
Composition 100% 
cotton 
100% 
cotton 
100% 
cotton 100% wool 100% wool 
100% 
leather 
100% 
acetate 
90% 
polyacryl-
amide, 
10% 
elastane 
65% poly-
ethylene, 
35% cotton 
65% poly-
ethylene, 
35% cotton 
80% wool, 
20% nylon 
Weaving Firmly Loosely Very firmly Loosely Firmly / Firmly Firmly Firmly Firmly Loosely 
Garment T-shirt T-shirt Sheet Jacket 
collar Jacket Jacket T-shirt T-shirt T-shirt T-shirt Jumper 
Color Unstained Dark grey Unstained Black Black Dark brown Dark grey Dark red Dark grey Red Dark green 
Blood spot            
10 µl + / +  + / + + / + + / + + / + + / + + / + + / + + / + + / + + / + 
2 µl + / + + / + + / + + / + + / + + / + + / + + / + + / + + / + + / + 
1 µl + / + + / + + / + + / + + / - + / + + / + + / + + / + + / + + / + 
0.5 µl + / + + / + + / - + / - + / + + / + + / + + / - + / + + / + + / + 
20 µl 1/2 + / + + / + + / + + / + + / + + / + + / + + / + + / + + / + + / + 
20 µl 1/5 + / + + / + + / + + / + + / + + / + + / - + / - + / + + / + + / + 
20 µl 1/10 + / + + / + + / - + / + + / + + / + + / + + / - - / - - / - + / + 
20 µl 1/20 + / + + / + - / - + / + + / + + / + - / - - / - - / - + / - + / + 
20 µl 1/50 
- /- + / + - / - + / - - / - - / - - / - - / - - / - - / - + / + 
20 µl 1/100 
- / - + / - - / - - / - - / - - / - - / - - / - - / - - / - + / + 
20 µl 1/500 
- / - - / - - / - - / - - / - - / - - / - - / - - / - - / - - / - 
+ / + Both blood spots on the fabric tested positive  
+ / -  Only one of the two blood spots tested positive  
-  / -  Both blood spots on the fabric tested negative  
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Conclusions 
Blood is a common type of body fluid found at crime scenes, particularly at scenes of violent crimes. 
On dark fabrics, it can be quite challenging to visually detect blood with the naked eye, hence 
visualization aids, such as Polilight, fluorescein test and luminol test, have been developed. All of 
these have one or more disadvantages, such as a potential negative impact on DNA quality, 
impracticality (e.g. necessity of fluorescent illumination or darkened room) and/or high cost. In an 
attempt to overcome these disadvantages, a visualization assay for the detection of blood on dark 
fabrics was optimized and validated in this study.  
This visualization assay, based on migration of blood to a filter paper through capillary forces, shows 
no negative influence on DNA quality of the stain. Moreover, presumptive blood tests to confirm the 
presence of blood and DNA profiling can be performed on the transferred bloodstains on the filter 
paper. Evaluation of the presence of blood can be performed after 30 minutes incubation, while the 
glass plate is still on top of the fabric, protecting it from potential contamination. It is easy to 
perform, requires little hands on time and is extremely cheap because only filter paper, water and 
two glass plates are needed. Moreover, the presented visualization assay does not disturb bloodstain 
pattern, which is an important part of the investigation and crime scene reconstruction.  
Although the visualization assay is less sensitive for diluted blood, this can be overcome by combining 
it with a standard presumptive blood test. Overall, it can be concluded that the presented 
visualization assay is easily applicable and is a valuable technique for visualization of blood on dark 
fabrics.  
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During this PhD thesis, several visualization techniques have been optimized to study clinical and 
forensic samples. The use of a microscope is of utmost importance to study these samples at the 
cellular and subcellular level. However, most fixed cells are hardly visible through a light microscope 
without staining techniques. Therefore, several staining techniques have been optimized and 
validated throughout this thesis in order to visualize male fetal microchimeric cells in blood of 
patients with an autoimmune thyroid disease and to count nuclei in hair roots in the context of 
forensic investigation. As blood is a common type of body fluid found at crime scenes but hardly 
visible on dark backgrounds, a method to visualize latent bloodstains on dark fabrics has been 
optimized (Part I). 
In a first part of this thesis, the potential role of fetal microchimeric cells in two common 
autoimmune thyroid diseases (AITDs), Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), was 
investigated (Part II). Fetal microchimerism refers to the presence of fetal cells in maternal blood and 
tissues during and after pregnancy, and is a well-known phenomenon in healthy persons as well as 
persons with a (autoimmune) disease (Part II, Chapter 1). HT is the most common cause of 
hypothyroidism, while GD the major cause of hyperthyroidism (Part II, Chapter 3).  
To identify male fetal microchimeric cells in women with a previous male pregnancy, two techniques 
have been most widely used: PCR targeting sequences specific to Y chromosome genes (e.g. DYS14 
and SRY) and Fluorescence in situ Hybridization (FISH) using X and Y chromosome specific probes. 
While PCR only indicates the presence of fetal cells and estimates the amount of fetal microchimeric 
cells, FISH gives an exact number. Both techniques have a different sensitivity. With PCR, a single 
male cell can be detected within a background of 100.000 female cells, compared to 1 male cell 
within 2 million female cells with FISH. Moreover, FISH can be used to locate fetal cells in a tissue 
section and at the same time, these cells can be characterized using fluorescently labelled antibodies. 
DAPI is used to stain all nuclei of the sample. Because of the higher sensitivity, FISH has been used in 
our study to identify male fetal microchimeric cells in blood of patients with HT or GD (Part II, 
Chapter 4). A disadvantage of FISH is the labour-intensive analysis of the results and the possible 
occurrence of false positive results. However, applying a second round of FISH with another Y 
chromosome probe decreases the number of false positive results. The search for desired cells on a 
slide can often be time consuming, especially if the cells of interest are rare. Image analysis software 
modules can be very helpful for the automatic detection of target cells, e.g. spermatozoa stained 
with Sperm HY-LITER™ and male buccal cells in an overwhelming amount of female cells [1,2]. 
Software can also be used to automatically count cell nuclei on a slide [3]. As male fetal 
microchimeric cells in maternal blood are rare, an image processing AxioVision Commander module 
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based on the detection of the Y chromosome spots, was used for the automatic detection of these 
cells. The cells automatically detected with the software, were relocated on the slide, and visual 
inspection of the cells was performed to make sure the detected cells were not false positives.  
More male fetal microchimeric cells were detected in blood of patients with GD or HT compared to 
healthy controls. At the same time, a significant difference in number of male fetal cells was 
observed between both groups of patients. Therefore, fetal microchimeric cells were characterized 
by enriching B, CD4
+
 T and CD8
+
 T cells prior to FISH. Our study focused on B and T cells as these cell 
types are more likely to initiate or be involved in immune response. In patients with HT, mainly male 
fetal CD8
+
 cytotoxic T cells were found. One might speculate that these fetal T cells could cause cell 
death leading to hypothyroidism. In patients with GD, the majority of male fetal cells was found in 
the B cell fraction. These fetal B cells could possibly be activated by fetal CD4
+
 T cells, which were 
also detected in blood of these patients. One might speculate that activation of fetal thyroid-specific 
CD4
+
 T cells leads to recruitment of autoreactive B cells. These B cells could secrete TSHR stimulating 
antibodies leading to hyperthyroidism. Although our results show a clear association of fetal 
microchimerism with AITD and indicate a potential harmful effect of these fetal cells in the 
pathogenesis of HT and GD, we have to keep in mind that results of this study are based on a limited 
number of patient samples and therefore should be confirmed in a larger data set. Even more, fetal 
microchimeric cells have to be characterized more in depth to define ‘the other cell types’. 
Several technical and clinical issues have to be considered if data on fetal microchimerism are 
compared. Differences in experimental design, sensitivity and specificity of the detection techniques 
(as mentioned above) could influence the results. Additionally, some reports lack data concerning 
pregnancy history which is important if fetal microchimerism is studied. Terminations of pregnancy 
for example, are associated with an elevated number of fetal microchimeric cells [4,5]. Moreover, 
alternative sources of microchimerism, natural or iatrogenic, should be taken into account as a 
recent publication stated that we are all born as microchimera [6]. Therefore, microchimeric cells 
should be isolated from the maternal blood in order to determine the possible origin of these cells. 
These microchimeric cells could have a fetal, maternal or grandmaternal origin, or could be 
originating from a blood transfusion. A possible technique to determine the origin, is to perform HLA 
typing on the isolated microchimeric cells and to compare the HLA type with their children, mother 
and other possible donors of the microchimeric cells. However, more research needs to be done on 
obtaining a pure population of microchimeric cells. 
These above mentioned concerns aside, fetal microchimerism has been shown to be more common 
in thyroid glands of patients with AITD compared to controls [7-9]. In contrast to thyroid tissue where 
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fetal cells could be detected in only 50% of patients with an AITD, fetal cells were detected in blood 
of all patients in our study. However, it is possible that in patients who appear to be negative for 
male fetal microchimerism, fetal cells could not be detected by the methods used due to their lack of 
sensitivity. Moreover, female instead of male fetal microchimeric cells could be present in blood 
and/or tissues of these patients. Up to now, female fetal microchimerism can only be identified 
based on differences in HLA between mother and fetus and is more difficult to study because the 
system requires multiple detection probes. During this PhD thesis, we have tried to optimize a HLA-
based detection technique. However, results were disappointing because of high background 
staining which could not be reduced despite several attempts to optimize the staining. Therefore, no 
software could be used for the automated detection of these rare cells. Optimizing staining 
techniques and development of more sophisticated detection techniques is mandatory to be able to 
detect female fetal microchimeric cells in blood and tissues of patients with an autoimmune (thyroid) 
disease. Once achieved, female microchimerism could also be studied in men with an autoimmune 
disease. 
In thyroid glands where the immune reaction is taking place, only the presence of fetal microchimeric 
cells has been proven [7-9]. To elucidate the potential role of fetal microchimeric cells in AITD, fetal 
microchimeric cells in the thyroid gland have to be characterized. Currently, preliminary data are 
obtained from thyroid glands of patients with GD. Although fetal cells were detected in their thyroid 
glands, characterization studies did not (yet) confirm the presence of fetal T or B cells. Further 
research to determine the fetal cell type in the thyroid gland is mandatory to assign a potential 
harmful effect of these cells in autoimmune thyroid diseases. If fetal cells detected in the thyroid 
gland do not turn out to be fetal B or T cells, other stainings need to be optimized and performed to 
determine the fetal cell type.    
To conclude the first part of the PhD thesis, a review discussing hypotheses about the potential role 
of fetal microchimeric cells in autoimmune (thyroid) diseases has been described (Part II, Chapter 5). 
Fetal cells could have harmful, beneficial or innocent effects for the thyroid gland. In a harmful way, 
fetal cells could cause autoimmune disease by initiating a graft-versus-host reaction, or the maternal 
host could initiate a host-versus-graft reaction against these fetal cells. Despite the fact that male 
fetal cells were only characterized in blood in a limited number of patient samples in our study, the 
presence of fetal CD8
+
 T cells in HT and fetal CD4
+
 T and B cells in GD was clearly shown. These results 
provide support for the hypothesis that fetal microchimeric cells could have a harmful effect in the 
thyroid gland in which fetal cells could initiate a graft-versus-host reaction in the mother. Our data 
indicate the value and need for further research in this field. A beneficial effect of fetal microchimeric 
PART IV 
 
 
 
150 
cells in which fetal cells could offer help in tissue repair, has mainly been described in breast and 
cervical cancer. A third hypothesis states that microchimeric cells are innocent bystanders in the 
process of autoimmunity as microchimeric cells have also been detected in healthy women. In our 
opinion however, the harmful, beneficial or innocent effect of fetal microchimerism depends on 
several factors including the type of fetal cells acquired, tissue environment and type of malignancy. 
More importantly, it seems that HLA similarities between fetal and maternal cells have the potential 
to affect the balance of beneficial versus harmful consequences for the mother. The more fetal 
microchimeric cells show HLA similarities with maternal cells, the less likely they are recognized by 
the maternal immune system and the more likely they have the potential to start a graft-versus-host 
reaction once they have been activated by yet undetermined mechanisms. Further investigation to 
confirm this hypothesis is required.  
Insights in the mechanism by which fetal microchimeric cells have potential harmful effects on 
autoimmune thyroid diseases, could lead to the development of a specific therapy targeting the fetal 
immune cells. In Graves’ disease for example, fetal B cells, possibly responsible for production of 
anti-thyroid stimulating antibodies causing hyperthyroidism, could be eliminated by Rituximab, a 
monoclonal antibody against CD20 which is primarily found on the surface of B cells. Rituximab is 
already used for the treatment of the autoimmune disease rheumatoid arthritis [10]. A side effect of 
this depletion therapy however, is that also non-autoreactive B cells are depleted. Therefore, it is 
important to search for a therapy that specifically targets the fetal cells. The first step however, is to 
get more insights in the mechanism on how fetal microchimeric immune cells could start an 
autoimmune response in the mother. 
In a second part of this thesis, two visualization techniques have been optimized for their use in 
forensic applications (Part III). In our lab, several (fluorescent) staining techniques have been 
developed to analyze forensic samples. In cases of sexual assault for example, FISH can be used to 
discriminate male cells of the perpetrator from female cells of the victim. Subsequently, male cells 
can be isolated using laser pressure catapulting in order to obtain a single DNA profile of the 
perpetrator instead of mixed DNA profiles, which are more difficult to interpret [2].  
The fluorescent stain DAPI has also its application in forensic research. We evaluated the use of DAPI 
to stain nuclear DNA in hair roots to predict their DNA analysis success rate (Part III, Chapter 2). 
Human hairs are frequently recovered as forensic evidence on crime scenes as humans shed around 
150 hairs daily. These hairs can be microscopically compared to reference hairs of the putative 
offender. However, the discriminative power of microscopic analysis of hairs is relatively small. 
Therefore, Short Tandem Repeat (STR) analysis of the hair root should be performed to identify the 
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donor of the hair. The success rate of STR profiling of hair roots however, is quite low and negative 
results of hair analysis are frequently reported. To increase the success rate, a screening method 
prior to DNA analysis should be performed to select hairs containing nuclear DNA. Nuclear DNA in 
hair roots can be stained with haematoxylin [11]. However, haematoxylin is known to reduce DNA 
yield and is therefore not recommended if these hair roots are submitted to DNA analysis afterwards. 
Another technique to visualize nuclear DNA, is labeling in situ [12]. As mentioned above, labeling in 
situ is very labor-intensive. Therefore, the use of DAPI to stain nuclear DNA in hair roots overnight 
has been proposed [13]. The current Belgium DNA law demands a forensic DNA report within a 
month. Therefore, protocols should be kept as short as possible. The aim of this study was to 
improve the staining technique for use in forensic DNA laboratories. We were able to reduce the 
incubation time from overnight to a direct staining and visualization of the hair root under the 
fluorescence microscope. DNA analysis of hair roots counting any nuclei, resulted in a success rate of 
94%. Without this screening method, a success rate of only 30% would have been achieved, which 
indicates the value of performing our fast screening method prior to DNA analysis. If hairs are 
collected from adhesive films, it can be interesting for DNA analysis to include that part of the tape 
where the hair root was located as loss of nuclei after removing the hair root from the adhesive film 
was observed. In an optimal situation, hair roots without visible nuclei should not be selected for 
DNA analysis since no profiles could be obtained in 96% of the analyzed samples. However, in 4% of 
these cases, a full or partial DNA profile could be obtained. This could possibly be due to adhering 
material around the hair root. Therefore, results of DAPI staining should always be considered in 
function of the importance of the evidential value of the found hair. If the hair is the only biological 
evidence in the forensic case and the staining is considered to be negative, one might consider to 
submit the hair to STR analysis anyway. Multiple hair roots having the same characteristics can be 
pooled for STR analysis, possibly increasing the chance of obtaining a DNA profile. If still no STR 
profile could be obtained, one might consider to submit the remainder of the hair to mitochondrial 
DNA analysis. However, mitochondrial DNA is the same in the maternal lineage and is therefore less 
discriminative to autosomal  STR analysis.  
This screening method has now been implemented in our forensic DNA laboratory. Similar results 
were obtained on hair roots selected from 36 forensic cases. Without this screening method, 279 
hair roots would have been submitted to DNA analysis, which is associated with a high judiciary cost. 
We only selected 16 hair roots for DNA analysis based on the presence of nuclei. DNA profiles could 
be obtained in 81% of these cases. In the remainder 19% however, less than 20 nuclei, which are 
required to obtain at least partial STR profiles, were detected. Moreover, we have to keep in mind 
that adverse environmental conditions prior to collection of hairs from crime scenes could influence 
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the results. These data indicate the value of this screening method in order to reduce judiciary costs. 
We recommend all forensic DNA laboratories to use this fast screening method for the selection of 
hairs suitable for DNA analysis. 
One of the first steps in the analysis of forensic evidence is the search for biological material that can 
subsequently be used for DNA extraction and profiling. Blood is a common body fluid detected on 
pieces of evidence found at crime scenes, especially at scenes of violent crimes. However, 
bloodstains on dark backgrounds, e.g. dark fabrics, are hard to see with the naked eye. Several 
visualization techniques such as Polilight, infrared detection, luminol based detection and fluorescein, 
have been suggested to locate blood spots on dark backgrounds. However, all are associated with 
one or more disadvantages, including the need to work in a dark room, the need for alternative light 
sources, the occurrence of false positive or false negative results, a high cost or negative influence on 
DNA quality. Therefore, the aim was to develop a simple, inexpensive visualization assay without the 
need of an alternative light source (Part III, Chapter 3). The presented visualization assay is based on 
the transfer of blood onto a filter paper through capillary forces in order to locate bloodstains on a 
dark piece of fabric. Small quantities of undiluted bloodstains on several kinds of fabrics can easily be 
detected with the presented assay. This is of utmost importance since most bloodstains found on 
forensic evidence are undiluted and present in small amounts. In case of diluted bloodstains, slightly 
better results were obtained for loosely woven natural fabrics compared to firmly woven synthetic 
fabrics. As this visualization assay is only a visualization aid for detecting bloodstains on dark fabrics, 
a positive result should always be confirmed by a presumptive blood test, e.g. Kastle-Meyer test.  
This presumptive blood test can be applied on the detected bloodstain on the fabric, but it can also 
be applied directly on the filter paper of the visualization assay, which is a major advantage of the 
presented technique. The human origin of the bloodstain can be confirmed using the Hexagon OBTI 
test. If no blood spots are visualized on the filter paper, this means that either no blood is present on 
the fabric or that the blood is diluted more than what is visually detectable with the visualization 
assay. In that case, one might consider to perform more sensitive and more expensive presumptive 
blood tests on several locations of the fabric. However, the most important bloodstains useful for 
DNA analysis will be detected with the visualization assay. Besides the low cost and the easiness to 
perform the assay, two important advantages for application in a routine forensic DNA laboratory, 
DNA analysis can be performed directly on the transferred bloodstains on the filter paper without 
the need to cut bloodstains from a piece of evidence. In case no DNA profile could be obtained from 
the transferred bloodstain on the filter paper, the stain on the fabric itself must be used for DNA 
analysis.  
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This visualization assay prior to other presumptive blood tests to detect latent blood spots on dark 
fabrics, is highly recommended for forensic laboratories as it is easy to perform and extremely cheap. 
Moreover, bloodstain pattern analysis, an important part of crime scene reconstruction, can be 
performed on the filter paper itself. As from now, the visualization assay will be performed in our 
DNA laboratory if bloodstains on dark fabrics have to be visualized. However, more research has to 
be done on mixtures of blood and other biological substances such as saliva and vomit, semen and 
menstrual blood, in order to determine the influence of these substances on the ability to visualize 
bloodstains and to perform DNA analysis on the transferred bloodstains.  
During this PhD thesis, several visualization techniques were optimized and validated in order to 
analyze clinical and forensic samples. However, the continuous development of new visualization 
techniques is necessary to analyze these samples more easily.  
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Tijdens deze doctoraatsthesis werden verschillende visualisatietechnieken geoptimaliseerd om 
klinische en forensische stalen te bestuderen. Het gebruik van een microscoop is belangrijk om deze 
stalen op cellulair en subcellulair niveau te bestuderen. De meeste gefixeerde cellen zijn echter 
moeilijk te zien doorheen een lichtmicroscoop zonder kleuringstechnieken. In het kader van deze 
thesis werden verschillende kleuringen geoptimaliseerd en gevalideerd om mannelijke foetale 
microchimere cellen in bloed van patiëntes met een auto-immune schildklieraandoening te 
detecteren en om, in het kader van forensisch onderzoek, nuclei in haarwortels te visualiseren. 
Aangezien bloed een vaak voorkomend type van lichaamsvloeistof is die teruggevonden wordt op 
een plaats van misdrijf, maar moeilijk zichtbaar is op donkere achtergronden, werd een methode 
geoptimaliseerd om bloedvlekken op donkere stoffen zichtbaar te maken (Deel I). 
In een eerste deel van deze thesis werd de potentiële rol van foetale microchimere cellen in twee 
auto-immune schildklieraandoeningen (AITD) onderzocht, namelijk de ziekte van Hashimoto (HT) en 
de ziekte van Graves (GD) (Deel II). Foetale microchimerie verwijst naar de aanwezigheid van foetale 
cellen in maternaal bloed en maternale weefsels tijdens en na de zwangerschap, en is een algemeen 
gekend fenomeen in zowel gezonde personen als personen met een (auto-immune) aandoening 
(Deel II, Hoofdstuk 1). HT is de meest voorkomende oorzaak van hypothyroïdie, terwijl GD de 
belangrijkste oorzaak van hyperthyroïdie is (Deel II, Hoofdstuk 3). 
Om mannelijke foetale microchimerie cellen in vrouwen die eerder een zoon hebben gebaard te 
identificeren, worden er voornamelijk twee technieken gebruikt: PCR met amplificatie van Y 
chromosomale specifieke sequenties (bv. DYS14 en SRY), en Fluorescentie in situ hybridisatie (FISH) 
met specifieke X en Y chromosomale probes. Met PCR kan enkel de aanwezigheid van foetale cellen 
aangetoond worden en een schatting gegeven worden van het aantal foetale cellen. Met FISH 
daarentegen, kan het aantal foetale cellen exact bepaald worden. Bovendien hebben beide 
technieken een verschillende sensitiviteit. Eén enkele mannelijke cel op 100.000 vrouwelijke cellen 
kan gedetecteerd worden met PCR, terwijl dit met FISH 1 mannelijke cel op 2 miljoen vrouwelijke 
cellen is. Tegelijkertijd kunnen foetale cellen gelokaliseerd en gekarakteriseerd worden in een 
weefselsectie door gebruik te maken van FISH in combinatie met fluorescent gelabelde antilichamen. 
DAPI wordt gebruikt om alle celkernen in een staal aan te kleuren. Omwille van de hogere 
sensitiviteit, werd FISH ook in onze studie toegepast om mannelijke foetale cellen in bloed van 
patiëntes met HT of GD te identificeren (Deel II, Hoofdstuk 4). Een nadeel van FISH is de 
arbeidsintensieve analyse van de resultaten en het voorkomen van vals-positieve resultaten. Door 
echter nogmaals FISH toe te passen maar nu met een andere Y chromosomale gelabelde probe, 
vermindert de kans op vals-positieve resultaten. De zoektocht naar de gewenste cellen op een slide 
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kan vaak tijdrovend zijn, vooral indien de cellen van interesse zeer zeldzaam zijn. Software modules 
voor beeldverwerking kunnen zeer handig zijn om de cellen van interesse automatisch te detecteren, 
bv. spermatozoa gekleurd met Sperm HY-LITER™ en mannelijke buccale cellen in een overgrote 
meerderheid van vrouwelijke cellen [1,2]. Bovendien kan bepaalde software ook gebruikt worden om 
automatisch het aantal celkernen op een slide te tellen [3]. Aangezien het aantal mannelijke 
microchimere cellen in maternaal bloed zeldzaam is, werd een beeldverwerkingsmodule van 
AxioVision gebruikt voor de automatische detectie van deze cellen. Het script is gebaseerd op de 
detectie van Y chromosomale spots. De automatisch gedetecteerde cellen werden opnieuw 
gelokaliseerd op de slide en werden onderworpen aan een visuele controle om er zeker van te zijn 
dat de gedetecteerde signalen geen vals positieve signalen waren.  
In vergelijking met gezonde controles werden meer mannelijke foetale cellen gedetecteerd in bloed 
van patiëntes met GD of HT. Tegelijkertijd werd een significant verschil in aantal mannelijke foetale 
cellen geobserveerd tussen beide groepen van patiëntes. Daarom werden, voorafgaand aan FISH, 
foetale cellen gekarakteriseerd door het aanrijken van B, CD4
+
 T en CD8
+
 T cellen. De focus van onze 
studie lag op detectie van foetale B en T cellen omdat deze celtypes meer waarschijnlijk een 
immuunreactie initiëren of daarin betrokken zijn. In patiëntes met HT werden voornamelijk 
mannelijke foetale CD8
+
 cytotoxische T cellen gevonden. Er kan gespeculeerd worden dat deze 
foetale T cellen celdood kunnen veroorzaken, en uiteindelijk hypothyroïdie. In patiëntes met GD 
werden voornamelijk mannelijke foetale B cellen aangetroffen. Deze foetale B cellen zouden 
vermoedelijk kunnen geactiveerd worden door foetale CD4
+
 T cellen, eveneens gedetecteerd in het 
bloed van deze patiëntes. We kunnen speculeren dat activatie van foetale schildklier-specifieke CD4
+
 
T cellen aanleiding geeft tot het rekruteren van autoreactive B cellen. Deze B cellen zouden dan 
TSHR-stimulerende antilichamen kunnen secreteren die aanleiding geven tot hyperthyroïdie. Hoewel 
onze resultaten een duidelijk associatie van foetale microchimerie met AITD en een potentieel 
schadelijk effect van deze cellen in de pathogenese van HT en GD aantonen, moeten we in het 
achterhoofd houden dat de resultaten van deze studie gebaseerd zijn op een beperkt aantal 
patiënten stalen en dat de resultaten bijgevolg moeten bevestigd worden in een grotere dataset. 
Bovendien moeten ‘de overige celtypes’ nog beter gekarakteriseerd worden. 
Indien data over foetale microchimerie vergeleken worden, moeten verschillende technische en 
klinische aspecten in overweging genomen worden. Verschillen in experimentele opzet, sensitiviteit 
en specificiteit van de detectietechnieken (zoals eerder vermeld) kunnen een invloed hebben op de 
resultaten. Bovendien missen sommige reporten data over de zwangerschapshistoriek, wat 
belangrijk is als foetale microchimerie bestudeerd wordt. Beëindiging van de zwangerschap 
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bijvoorbeeld, wordt geassocieerd met een verhoogd aantal foetale microchimere cellen [4,5]. 
Bovendien moeten alternatieve, natuurlijke of iatrogene, bronnen van microchimerie in rekening 
gebracht worden aangezien in een recente publicatie wordt gesteld dat we allemaal geboren worden 
als microchimera [6]. Het is daarom van belang om de microchimere cellen te isoleren uit maternaal 
bloed om de mogelijke bron van deze cellen te achterhalen. Deze microchimere cellen kunnen een 
foetale of maternale oorsprong hebben, of kunnen zelfs afkomstig zijn van de grootmoeder. 
Bovendien kunnen deze cellen ook verkregen zijn via een bloedtransfusie. Een mogelijke techniek om 
de oorsprong van deze cellen te bepalen, is via HLA typering om vervolgens het HLA type van deze 
microchimere cellen te vergelijken met het HLA type van hun kinderen, moeder en andere mogelijke 
donoren van de microchimere cellen. Meer onderzoek is echter in eerste instantie nodig om een 
pure populatie van microchimere cellen te bekomen voor HLA typering.  
Deze bedenkingen terzijde, werden er meer foetale microchimere cellen aangetoond in schildklieren 
van patiëntes met AITD in vergelijking met controles [7-9]. In tegenstelling tot schildklierweefsel 
waar foetale cellen slechts gedetecteerd werden in 50% van de patiëntes met AITD, werden foetale 
cellen aangetoond in het bloed van alle patiëntes in onze studie. Het is echter mogelijk dat in 
patiëntes die geen mannelijke foetale microchimere cellen blijken te bezitten, foetale cellen niet 
gedetecteerd werden door het gebrek aan een hoge sensitiviteit van de gebruikte detectietechniek. 
Bovendien kunnen vrouwelijke in plaats van mannelijke foetale microchimere cellen aanwezig zijn in 
bloed en/of weefsels van deze patiëntes. Tot nu toe kunnen vrouwelijke foetale microchimere cellen 
enkel bestudeerd worden aan de hand van HLA verschillen tussen moeder en foetus. Dit is moeilijker 
te bestuderen omdat meerdere detectieprobes noodzakelijk zijn. In de loop van deze thesis werd 
getracht om een HLA-gebaseerde detectie techniek te optimaliseren. Resultaten waren echter 
teleurstellend omwille van de hoge achtergrondkleuring welke niet gereduceerd kon worden 
ondanks verschillende optimalisatiepogingen. Er kon daarom geen software ontwikkeld worden voor 
de automatische detectie van deze zeldzame cellen. Optimalisatie van kleuringstechnieken en 
ontwikkeling van meer gesofisticeerde detectie methoden is vereist om vrouwelijke foetale 
microchimere cellen te visualiseren in bloed en weefsels van patiëntes met een auto-immune 
(schildklier)aandoening. Eenmaal deze doelstelling bereikt is, kan ook vrouwelijke microchimerie in 
mannen met een auto-immune aandoening bestudeerd worden. 
Enkel de aanwezigheid van foetale microchimere cellen in de schildklier, waar de immuunreactie 
plaats vindt, werd bewezen [7-9]. Om de potentiele rol van foetale microchimere cellen in AITD op te 
helderen, moeten deze cellen in de schildklier gekarakteriseerd worden. Momenteel worden 
preliminaire data verwerkt omtrent de foetale cellen in schildklieren van patiëntes met GD. Hoewel 
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foetale cellen gedetecteerd werden in hun schildklieren, bevestigden de karakteriseringsstudies (nog) 
niet de aanwezigheid van foetale T of B cellen. Verder onderzoek om het foetale celtype in de 
schildklier te bepalen is noodzakelijk om een mogelijks potentieel schadelijk effect van deze cellen in 
auto-immune schildklieraandoeningen toe te schrijven. Indien de foetale microchimere cellen in de 
schildklier geen T of B cellen blijken te zijn, dan zullen verdere kleuringen geoptimaliseerd moeten 
worden om het foetale celtype te bepalen. 
Het eerste deel van deze doctoraatsthesis wordt afgesloten met een review waarin de mogelijke 
hypotheses omtrent de potentiele rol van foetale microchimere cellen in auto-immune 
(schildklier)aandoeningen aangehaald worden (Deel II, Hoofdstuk 5). Foetale cellen kunnen een 
nadelig, voordelig of onschuldig effect hebben voor de schildklier. Op een nadelige manier kunnen 
foetale cellen auto-immune aandoeningen veroorzaken door een ‘graft-versus-host’ reactie te 
initiëren, of de moeder zou een ‘host-versus-graft’ reactie tegen deze foetale cellen kunnen starten. 
Ondanks het feit dat mannelijke foetale cellen enkel gekarakteriseerd werden in het bloed van een 
beperkt aantal patiëntes in onze studie, werd de aanwezigheid van foetale CD8
+
 T cellen in HT en 
foetale CD4
+
 T en B cellen in GD duidelijk aangetoond. Deze resultaten ondersteunen de hypothese 
dat foetale microchimere cellen een nadelig effect voor de schildklier kunnen hebben waarbij de 
foetale cellen een ‘graft-versus-host’ reactie in de moeder kunnen initiëren. Onze data ondersteunen 
de waarde en de nood voor verder onderzoek in dit onderzoeksveld. Een voordelig effect van foetale 
microchimere cellen waarbij deze cellen hulp zouden kunnen bieden in het herstel van weefsels, 
werd voornamelijk beschreven in borst- en baarmoederhalskanker. Een derde hypothese 
veronderstelt dat de microchimere cellen onschuldige omstanders zijn in het proces van auto-
immuniteit aangezien microchimere cellen ook gedetecteerd werden in gezonde vrouwen. In onze 
opinie echter, hangt het nadelig, voordelig of onschuldig effect van foetale microchimere cellen 
voornamelijk af van een aantal factoren zoals het foetale celtype dat verkregen werd, de 
weefselomgeving en het type van aandoening. Nog belangrijker blijkt dat HLA-gelijkenissen tussen 
foetale en maternale cellen het potentieel hebben om de balans tussen voordelige en nadelige 
gevolgen voor de moeder te beïnvloeden. Hoe meer foetale microchimere cellen HLA-gelijkenissen 
vertonen met maternale cellen, hoe minder waarschijnlijk zij herkend worden door het maternale 
immuunsysteem en hoe meer waarschijnlijk zij het potentieel hebben om een ‘graft-versus-host’ 
reactie te starten eenmaal zij geactiveerd worden door nog onbekende mechanismen. Verder 
onderzoek om deze hypothese te bevestigen is noodzakelijk.  
Inzicht in het mechanisme hoe foetale microchimere cellen een potentieel schadelijk effect kunnen 
hebben in het ontstaan van auto-immune schildklieraandoeningen, zou aanleiding kunnen geven tot 
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de ontwikkeling van een specifieke therapie die de foetale immuun cellen als target heeft. In de 
ziekte van Graves bijvoorbeeld, zouden foetale B cellen, die mogelijks verantwoordelijk zijn voor de 
productie van anti-schildklier stimulerende antilichamen die leiden tot hyperthyroïdie, geëlimineerd 
kunnen worden door Rituximab, een monoklonaal antilichaam tegen CD20, een oppervlakte merker 
van B cellen. Rituximab wordt reeds gebruikt in de behandeling van de auto-immune aandoening 
reumatoïde artritis [10]. Een bijwerking van deze depletietherapie echter is het feit dat ook niet-
autoreactieve B cellen worden gedepleteerd. Daarom is het noodzakelijk om op zoek te gaan naar 
een therapie die specifiek de foetale cellen als target heeft. De eerste stap daarin echter, is inzicht te 
verkrijgen in het mechanisme hoe foetale microchimere cellen een auto-immune reactie in de 
moeder zouden kunnen starten. 
In een tweede deel van deze thesis werden twee visualisatietechnieken geoptimaliseerd voor hun 
gebruik in forensische toepassingen (Deel III). In ons labo werden verschillende (fluorescente) 
kleuringen ontwikkeld voor de analyse van forensische stalen. In geval van seksuele aanranding 
bijvoorbeeld, kan FISH gebruikt worden om mannelijke cellen van de aanvaller te onderscheiden van 
vrouwelijke cellen van het slachtoffer. Vervolgens kunnen mannelijke cellen geïsoleerd worden door 
middel van laser microdissectie om een enkelvoudig DNA profiel van de dader te verkrijgen in plaats 
van een DNA-mengprofiel wat moeilijker te interpreteren is [2].  
De fluorescente kleurstof DAPI heeft ook zijn toepassing in forensisch onderzoek. Het gebruik van 
DAPI werd geëvalueerd om nucleair DNA in haarwortels aan te kleuren om het DNA analyse 
slaagpercentage van het haar te kunnen voorspellen (Deel III, Hoofdstuk 2). Humane haren worden 
frequent als forensisch bewijs op misdaadplaatsen verzameld aangezien mensen ongeveer 150 haren 
per dag verliezen. Deze haren kunnen microscopisch vergeleken worden met referentie haren van de 
vermoedelijke dader. Het onderscheidingsvermogen van microscopisch haaronderzoek is echter 
relatief klein. ‘Short Tandem Repeat’ (STR) analyse van de haren zou daarom uitgevoerd moeten 
worden om de donor van het haar te identificeren. Het slaagpercentage van STR analyse van haren is 
echter zeer laag en negatieve resultaten van haaranalyse worden frequent gerapporteerd. Om het 
slaagpercentage te doen stijgen, zou een screeningsmethode voorafgaand aan de DNA analyse 
uitgevoerd moeten worden om de haren met nucleair DNA te selecteren. Nucleair DNA in 
haarwortels kan gekleurd worden met haematoxyline [11]. Haematoxyline vermindert echter de DNA 
opbrengst en is daarom niet aanbevolen als de haarwortels na kleuring nog moeten gebruikt worden 
voor DNA analyse. Een andere methode om nucleair DNA te visualiseren, is door het nucleair DNA in 
situ te labelen [12]. Zoals eerder vermeld is in situ labelen een zeer arbeidsintensieve techniek. 
Daarom werd voorgesteld om nucleair DNA in haarwortels te kleuren met DAPI met een incubatie 
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overnacht [13]. De huidige Belgische DNA wet eist een forensisch DNA rapport binnen de maand. 
Daarom moeten protocollen zo kort mogelijk gehouden worden. Het doel van deze studie was om de 
kleuringstechniek te optimaliseren en in te korten om te kunnen gebruiken in forensische DNA 
laboratoria. We waren in staat om de incubatie tijd te reduceren van een kleuring overnacht tot een 
directe kleuring en visualisatie van de haarwortel onder de fluorescentiemicroscoop. DNA analyse 
van de haarwortels waarbij kernen werden geobserveerd, resulteerde in een slaagpercentage van 
94%. Zonder deze screeningsmethode zou echter maar een slaagpercentage van 30% bereikt worden, 
wat de waarde van onze screeningsmethode voorafgaand aan DNA analyse aantoont. Indien haren 
verzameld worden van kleeffilms, kan het interessant zijn voor DNA analyse om het deel van de 
kleeffilm te includeren daar waar de haarwortel gelokaliseerd was. Er werd namelijk een verlies van 
kernen gezien na verwijderen van de haarwortel van de kleeffilm. In een optimale situatie zouden 
haren zonder zichtbare kernen niet geselecteerd worden voor DNA analyse aangezien geen DNA 
profiel kon bepaald worden in 96% van de geanalyseerde stalen. In 4% van deze gevallen echter, 
konden volledige of gedeeltelijke DNA profielen bepaald worden. Dit zou te wijten kunnen zijn aan 
materiaal rond de haarwortel. Het resultaat van de DAPI kleuring zou daarom altijd beschouwd 
moeten worden in functie van het belang van de bewijswaarde van het gevonden haar. Als het haar 
het enige biologische bewijs is in een forensische zaak en de kleuring wordt negatief beschouwd, zou 
men kunnen overwegen om het haar toch te analyseren. Meerdere haren met dezelfde 
eigenschappen zouden samen genomen kunnen worden voor DNA analyse, waardoor de kans op een 
DNA profiel eventueel verhoogd zou kunnen worden. Indien nog steeds geen DNA profiel bepaald 
kan worden, zou men kunnen overwegen om een mitochondriaal DNA-profiel op het restant van het 
haar te bepalen. Mitochondriaal DNA is echter hetzelfde in de maternale lijn en is daarom minder 
onderscheidend  in vergelijking met autosomale STR analyse.  
Deze snelle screeningsmethode is momenteel geïmplementeerd in ons forensisch DNA laboratorium. 
Gelijkaardige resultaten werden verkregen op haarwortels die geselecteerd werden uit 36 
forensische zaken. Zonder deze screeningsmethode zou men 279 haarwortels geanalyseerd hebben, 
wat gepaard gaat met een hoge gerechtskost. Op basis van de aanwezigheid van kernen in de 
haarwortel, werden uiteindelijk maar 16 haren geselecteerd voor DNA analyse. Er werd een DNA 
profiel verkregen in 81% van de gevallen. In de resterende 19% van de haarwortels echter, werden 
minder dan 20 kernen geobserveerd. Uit experimentele data bleek echter dat minimum 20 nuclei 
noodzakelijk zijn voor op zijn minst gedeeltelijke DNA profielen te kunnen verkrijgen. Bovendien 
moeten we rekening houden met het feit dat ongunstige weersomstandigheden voorafgaand aan het 
verzamelen van de haren op de plaats van de misdaad, een invloed kunnen hebben op de resultaten. 
Deze data tonen de waarde van deze screeningsmethode aan om de gerechtskosten te beperken tot 
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een minimum. Wij bevelen alle forensische DNA laboratoria aan om deze snelle screeningsmethode 
toe te passen voor het selecteren van haren die geschikt zijn voor DNA analyse.  
Een van de eerste stappen in het analyseren van forensisch bewijs, is de zoektocht naar biologisch 
materiaal dat kan gebruikt worden voor DNA extractie en analyse. Bloed is een vaak voorkomend 
lichaamsvloeistof dat gedetecteerd wordt op overtuigingsstukken gevonden op de plaats van de 
misdaad, vooral indien het gaat om misdaden met geweld. Bloedvlekken op donkere achtergronden 
echter, bijvoorbeeld op donkere stoffen, zijn moeilijk zichtbaar met het blote oog. Verschillende 
visualisatietechnieken zoals Polilight, infrarood detectie, luminol gebaseerde detectietechnieken en 
fluoresceïne, werden voorgesteld om bloedvlekken op donkere achtergronden te lokaliseren. Er zijn 
echter één of meerdere nadelen verbonden met deze technieken, zoals de nood om te werken in 
een donkere kamer, de nood aan alternatieve lichtbronnen, het voorkomen van vals positieve of vals 
negatieve resultaten, een hoge gerechtskost of een negatief effect op DNA. Het doel van deze studie 
was om een eenvoudige, goedkope visualisatietechniek te ontwikkelen zonder de nood aan een 
alternatieve lichtbron (Deel III, Hoofdstuk 3). De voorgestelde visualisatietest is gebaseerd op de 
transfer van bloed naar een filterpapier doorheen capillaire krachten om bloedvlekken op een 
donker stuk stof te kunnen lokaliseren. Kleine hoeveelheden onverdund bloed op verschillende 
soorten stoffen kunnen gemakkelijk gedetecteerd worden met deze techniek. Dit is uitermate 
belangrijk aangezien de meeste bloedvlekken op forensisch bewijs onverdund en in minieme 
hoeveelheden aanwezig zijn. In geval van verdunde bloedvlekken worden enigszins betere resultaten 
verkregen op los geweven, natuurlijke stoffen in vergelijking met vast geweven, synthetische stoffen. 
Aangezien deze visualisatietechniek enkel een hulpmiddel is om bloedvlekken te visualiseren op 
donkere stoffen, zou een positief resultaat altijd bevestigd moeten worden met een algemene 
bloedtest, zoals de Kastle-Meyer test.  
Deze algemene bloedtest kan dan uitgevoerd worden op de gedetecteerde bloedvlek op de stof, 
maar het kan ook rechtstreeks uitgevoerd worden op het filterpapier van de visualisatietest, wat een 
belangrijk voordeel is van de voorgestelde techniek. De humane oorsprong van de bloedvlek kan 
bevestigd worden met een Hexagon OBTI test. Indien geen bloedvlekken worden gevisualiseerd op 
het filterpapier, dan kan dit betekenen dat er ofwel geen bloed aanwezig is op de stof of dat het 
bloed meer verdund is dan wat visueel gezien wordt met de test. In dat geval kan men overwegen 
om meer sensitieve en duurdere bloedtesten uit te voeren op verschillende locaties op de stof. 
Echter, de belangrijkste bloedvlekken die bruikbaar zijn voor DNA analyse zullen gedetecteerd 
worden met deze visualisatietechniek. Naast de lage kost en het gemak om deze test uit te voeren, 2 
belangrijke voordelen in een routine forensisch DNA laboratorium, kan DNA analyse ook direct 
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uitgevoerd worden op de getransfereerde bloedvlek op het filterpapier zonder dat de bloedvlek 
uitgeknipt dient te worden uit het bewijsstuk. Indien geen DNA profiel verkregen kan worden van de 
bloedvlek op het filterpapier, dient de vlek op de stof zelf uitgeknipt te worden voor DNA analyse.  
De visualisatietechniek voorafgaand aan andere bloedtesten om latente bloedvlekken op donkere 
stoffen op te sporen, is ten zeerste aanbevolen aan forensische laboratoria aangezien het zeer 
goedkoop en makkelijk uit te voeren is. Bovendien kan het patroon van de bloedvlek, wat een 
belangrijk onderdeel is van de misdaadreconstructie, uitgevoerd worden op het filterpapier zelf. Van 
nu af aan zal deze visualisatietechniek gebruikt worden in ons forensisch DNA laboratorium om 
bloedvlekken op donkere stoffen zichtbaar te maken. Meer onderzoek op mengsels van bloed en 
andere biologische substanties zoals speeksel en braaksel, semen en menstrueel bloed, is echter 
noodzakelijk om de invloed van deze substanties op de visualisatie na te gaan, alsook de invloed van 
deze substanties op de daaropvolgende DNA analyse uitgevoerd op de vlek op het filter papier.  
Gedurende deze PhD thesis werden verschillende visualisatietechnieken geoptimaliseerd en 
gevalideerd om klinische en forensische stalen te analyseren. De continue ontwikkeling van nieuwe 
visualisatietechnieken is echter noodzakelijk om gemakkelijker deze stalen te analyseren. 
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Abstract  
Persistence of fetal microchimeric cells may result in the development of autoimmune thyroid 
diseases (AITDs) such as Hashimoto’s thyroiditis (HT) or Graves’ disease (GD).  In women, HT and GD 
show an increased incidence in the years following parturition. Although fetal cells have already been 
shown to be more common in the thyroid glands of patients with an AITD compared to controls, 
these cells haven’t been described in blood of these patients. Our study detected male fetal cells in 
blood of all patients with an AITD.  Moreover, male fetal cells were immune cells potentially capable 
of initiating a graft-versus-host reaction and suggest a potential role of these cells in the 
pathogenesis of AITD. Our study indicates the value and need for further research in this field. 
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During pregnancy, fetal cells cross the placenta into the maternal circulation [1,2] and can persist in 
the postpartum period in tissues such as the thyroid gland [3]. The mother becomes microchimeric 
[4-6]. The persistence of these fetal cells may result in the development of autoimmune thyroid 
diseases (AITD) [7,8] such as Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) [9-11].  
The presence of male fetal cells can be investigated by real-time PCR or Fluorescence In Situ 
Hybridization (FISH) using male-specific markers in women who had given birth to a son. While real-
time PCR only indicates the presence of fetal cells and estimates the amount of fetal cells [7], FISH 
gives an exact number [5,6]. Therefore, data obtained by real-time PCR are hard to compare with 
those obtained by FISH, as shown by Renne et al. [5]. Using real-time PCR, the authors detected male 
fetal microchimerism in 38% of the patients with HT, compared to 83% using FISH. The differences 
might be explained by different sensitivities of both techniques [12]. With real-time PCR, a single 
male cell can be detected within a background of 100.000 female cells [13] compared to 1 male cell 
within 2.000.000 female cells with FISH [14]. Therefore, our study used the latter technique to detect 
male fetal cells in blood of women with an AITD.  
Male fetal microchimerism has already been shown to be more common in the thyroid glands of 
patients with AITD compared to controls [4-6,15,16]. Using real-time PCR, Klintshar et al. detected 
male fetal cells in 47% of the thyroid glands of patients with AITD compared to 4% of women with 
nodular goiter [4]. Later, the authors expanded the inquiry with a quantitative PCR-based approach, 
amplifying the DYS14 region of the Y chromosome, a technique that allows greater sensitivity 
because of multiple repeats [15]. This study identified male DNA in 38% of women with HT, in 5% of 
women with multinodular goiter and 0% of women with normal thyroid glands. In 20% of patients 
with GD, male fetal cells were detected in paraffin-embedded thyroid tissue compared to 0% in 
women with adenoma [16]. However, examining fresh-frozen thyroid tissues, male fetal 
microchimeric cells were detected in 85% of patients with GD compared to 25% of patients with 
adenoma, showing that paraffin-embedded tissue is subject to DNA fragmentation. Using FISH, 
Renne et al. [5] found that 60% of women with HT, 40% of women with GD and 22% of patients with 
thyroid adenoma were positive for male fetal cells in the thyroid. Using the same technique, Srivatsa 
et al. [6] detected male fetal cells in 72% of women with an AITD compared to 0% in healthy controls.  
In contrast to thyroid tissue, male fetal cells were detected in blood of all patients with an AITD in 
our study [14]. The highest number of male fetal cells was observed in patients with GD (14 to 29 
male fetal cells per million maternal cells), followed by HT (7 to 11) compared to the low number of 
male fetal cells detected in healthy volunteers (0 to 5). This indicates a higher degree of 
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microchimerism in AITD compared to healthy controls (p < 0.05). Moreover, significantly more male 
fetal cells were detected in patients with GD compared to patients with HT (p = 0.0061) [14].  
The etiologic consequences of fetal microchimerism are difficult to assess to date. Up to now, only 
the presence of fetal engrafted cells in AITD is proven, but not an actual active role of 
microchimerism in the autoimmune process. An argument against an active role is that only a part of 
all patients with AITD show male microchimerism in their thyroid [4-6,15,16]. Nevertheless, in 
patients who appear to be negative, it is possible that male fetal microchimerism is not detectable by 
the methods used or the fact that only female fetal cells are present [4]. In our study however, male 
fetal cells were detected in all patients with an AITD. Taken together, these data suggest a potential 
role of these cells in the pathogenesis of AITD [13,17]. 
If fetal cells indeed play a role in AITD, it is expected that fetal cells are pluripotent stem cells or 
immune cells. Male fetal CD34
+
 and CD34
+
/CD38
+
 progenitor cells, capable of differentiating into 
immune competent cells [3], but also mature male fetal T, B and NK cells [18] have been isolated 
from the blood of women with scleroderma, an autoimmune disease of the skin. Cha et al. [19] 
suggested that fetal progenitor cells may differentiate in the maternal host and might alter immune 
function. Fetal immune cells may be reactive to maternal antigens [20] and, therefore, have the 
capacity to trigger graft-versus-host reactions. It is possible that fetal cells also elicit an intrathyroidal 
graft-versus-host reaction that leads to AITD [5]. Ando et al. [16] and Davies et al. [21] propose that 
after delivery, when placental tolerogenic mechanisms are lost, intrathyroidal fetal immune cells are 
activated and initiate a graft-versus-host reaction against maternal antigens resulting in the 
activation of maternal autoreactive T cells which could eventually modulate AITD postpartum.  
Our study focused on the presence of male fetal B and T cells in blood of women with an AITD 
because these subsets are more likely to initiate or be involved in immune response. Mainly male 
fetal CD8
+
 cytotoxic T cells were found in blood of patients with HT, possibly causing cell death 
leading to hypothyroidism [14,22]. In blood of patients with GD, mainly male fetal B cells were found 
which are possibly activated by male fetal CD4
+
 T cells, also detected in their blood [14]. Activated B 
cells could secrete TSHR-stimulating antibodies which could lead to hyperthyroidism [22]. Other male 
fetal cell types not isolated during selection of T and B cells, are likely to be natural killer (NK) cells or 
hematopoietic progenitor cells capable of differentiating into immune competent cells [18]. Our 
study indicates the value and need for further research in this field.  
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